Document:

SERIES A CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT

 Exhibit 10.50 
 SERIES A CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT 
 This Series A
Convertible Preferred Stock Purchase Agreement dated as of October 19, 2005 (the “Agreement”) by and among Allozyne, Inc., a Delaware corporation (the “Company”), the Institute for Systems Biology, a Washington
non-profit corporation (“ISB”), ISB Accelerator Corporation, a Delaware corporation (“Accelerator”), Deepshikha Datta, an individual (“Datta”), William A. Goddard, an individual
(“Goddard”), and David Tirrell, an individual (“Tirrell”; Datta, Goddard, and Tirrell are each referred to as a “Founder” and collectively as the “Founders”), and the several
purchasers named in the attached Schedule I (individually a “Purchaser” and collectively the “Purchasers”; the Purchasers, ISB and Accelerator are each individually an “Investor” and
collectively the “Investors”): 
 WITNESSETH: 

WHEREAS, the Company wishes to issue and sell to the Purchasers up to an aggregate of 3,400,000 shares (the “Preferred
Shares”) of the authorized but unissued Series A Convertible Preferred Stock, par value $0.001 per share, of the Company (the “Series A Preferred Stock”) at the Closing (as set forth in Article 1 below); 

WHEREAS, the Purchasers, severally, wish to purchase the Preferred Shares on the terms and subject to the conditions set forth in this
Agreement; 
 WHEREAS, Company wishes to receive certain management, business and scientific services from Accelerator, ISB and
certain faculty and staff of ISB; 
 WHEREAS, in connection with receiving such services from Accelerator and in consideration
for Accelerator entering into a Master Work Agreement dated as of the date hereof, the Company wishes to issue to Accelerator one or more Warrants (as defined below) to purchase up to an aggregate of 1,072,580 shares of the Company’s common
stock, par value $0.001 per share (the “Common Stock”), at the Closing (as defined below); and 
 WHEREAS, in
connection with receiving such services from ISB and certain faculty and staff of ISB and in consideration for (i) the cash purchase price set forth on Schedule II hereof and (ii) ISB entering into a Services Agreement dated as of
the date hereof, the Company wishes to issue to ISB an aggregate of up to 858,065 shares of Common Stock (the “ISB Shares”) at the Closing. 
 NOW, THEREFORE, in consideration of the premises and the mutual covenants contained in this Agreement, the parties agree as follows: 

ARTICLE I 
 THE
PREFERRED SHARES, ISB SHARES AND WARRANTS 
 SECTION 1.1 Issuance, Sale and Delivery of the Preferred Shares; ISB Shares and
Warrants 

 (a) Subject to the terms and conditions of this Agreement, the Company shall
issue and sell to each Purchaser at the Closing, and each Purchaser shall, severally and not jointly, purchase from the Company at the Closing, the number of Preferred Shares set forth opposite the name of such Purchaser under the heading
“Number of Preferred Shares to be Purchased” on Schedule I attached hereto, for the aggregate purchase price set forth opposite the name of such Purchaser under the heading “Aggregate Purchase Price for Preferred Shares”.
The purchase price per share shall be $1.00. 
 (b) Subject to the terms and conditions of this Agreement, the
Company shall issue to ISB at the Closing the number of ISB Shares set forth next to the heading “Number of Shares of Common Stock” on Schedule II attached hereto, for the aggregate cash purchase price set forth under the heading
“Aggregate Purchase Price for ISB Shares”. The cash purchase price per share shall be $0.01. 
 (c)
Subject to the terms and conditions of this Agreement, the Company shall. issue to Accelerator at the Closing one or more warrants, substantially in the form attached hereto as Exhibit A (each a “Warrant” and collectively the
“Warrants”), in the names set forth on Schedule III attached hereto, and in the amounts set forth on such schedule opposite such names under the heading “Warrants to Purchase Common Stock”. The Warrants shall have
an exercise price per share equal to $0.10 per share of Common Stock. 
 SECTION 1.2 Closing. The closing shall take
place at the offices of Latham & Watkins LLP at 633 West Fifth Street, Suite 4000, Los Angeles, CA 90071, at 10:00 a.m., Los Angeles time on October 19, 2005, or at such other location, date and time as may be agreed upon between the
Purchasers and the Company (such closing being called the “Closing” and the date and time such Closing occurs being called the “Closing Date”). At the Closing, the Company shall: 

(a) Issue and deliver to each Purchaser a stock certificate or certificates in definitive form; registered in the name of
such Purchaser, representing the Preferred Shares being purchased by it at the Closing, as set forth on Schedule I. As payment in full for the Preferred Shares being purchased by it under this Agreement at the Closing, and against delivery of
the stock certificate or certificates representing such Preferred Shares, registered in the name of such Purchaser, on the Closing Date, each Purchaser shall (i) deliver to the Company a check payable to the order of the Company, in the amount
set forth opposite the name of such Purchaser under the heading “Aggregate Purchase Price for the Shares” on Schedule I, (ii) transfer such sum to the account of the Company by wire transfer, (iii) deliver to the Company
for cancellation promissory notes issued by the Company in the amount of such sum, or (iv) deliver or transfer such sum to the Company by any combination of such methods of payments. 

(b) Issue and deliver to ISB a stock certificate or certificates in definitive form, registered in the name of ISB,
representing the number of ISB Shares to be issued at the Closing, as set forth on Schedule II. As payment in full for the ISB Shares being purchased by ISB under this Agreement at the Closing, and against delivery of the stock certificate or
certificates representing such ISB Shares, registered in the name of ISB, on the Closing Date, ISB shall (i) deliver to the Company a check payable to the order of the Company, in the amount

  
 2 

 
set forth opposite the name of ISB under the heading “Aggregate Purchase Price for the ISB Shares” on Schedule II, (ii) transfer such sum to the account of the Company by
wire transfer, (iii) deliver to the Company for cancellation promissory notes issued by the Company in the amount of such sum, or (iv) deliver or transfer such sum to the Company by any combination of such methods of payments. 

(c) Issue and deliver to Accelerator one or more Warrants, in definitive form, registered in the names set forth on
Schedule III, to purchase the number of shares of Common Stock as set forth on such schedule opposite such names under the heading “Warrants to Purchase Common Stock”. 

SECTION 1.3 Use of Proceeds. The Company shall use the proceeds from the sale of the Preferred Shares (a) toward successful
achievement of the milestones set forth on Exhibit B hereto (the “Milestones”) and (b) for working capital and general corporate purposes pursuant to the Company’s written plan as previously delivered to the
Purchasers. 
 ARTICLE II 
 REPRESENTATIONS AND WARRANTIES OF THE COMPANY AND FOUNDERS 
 On and as of the
Closing Date, the Company represents and warrants (except as to Section 2.9(b), to which the Company and each Founder, jointly and severally, represent and warrant) to the Investors that, except as set forth in the Disclosure Schedule attached
as Schedule IV (the “Disclosure Schedule”) which Disclosure Schedule shall be arranged in paragraphs corresponding to the numbered and lettered paragraphs contained in this Article II; provided, that
the disclosures in the Disclosure Schedule shall qualify any numbered and lettered paragraph contained in this Article II (whether or not referenced) to which such disclosures apply if the applicability of such disclosure to such
non-referenced paragraphs is reasonably apparent on its face; and where indicated in this Article II that a representation or warranty is limited “to the Company’s knowledge,” or a phrase of similar import, such knowledge shall
include the knowledge of each Founder: 
 SECTION 2.1 Organization, Qualifications and Corporate Power. 

(a) The Company is a corporation duly incorporated, validly existing and in good standing under the laws of the State of
Delaware and is duly licensed or qualified to transact business as a foreign corporation and is in good standing in each jurisdiction in which the nature of the business transacted by it or the character of the properties owned or leased by it
requires such licensing or qualification. The Company has the corporate power and authority to own and hold its properties and to carry on its business as now conducted and as proposed to be conducted, to execute, deliver and perform this Agreement,
the Investor Rights Agreement in the form attached as Exhibit C (the “Investor Rights Agreement”), the Stockholders Agreement in the form attached as Exhibit D (the “Stockholders Agreement”) and the
Amended and Restated Stock Restriction Agreements in the form attached as Exhibit E (collectively, the “Stock Restriction Agreements”; this Agreement, the Investor Rights Agreement, the Stockholders Agreement and the Stock
Restriction Agreements are collectively referred to as the “Transaction Documents”), to issue, sell and deliver the Preferred Shares, to issue and deliver the ISB Shares, 

  
 3 

 
to issue and deliver the Warrants, and to issue and deliver the shares of Common Stock issuable upon conversion of the Preferred Shares (the “Conversion Shares”) and the shares
of Common Stock issuable upon exercise of the Warrants (the “Warrant Shares”). 
 (b) The
Company has no subsidiaries and does not (i) own of record or beneficially, directly or indirectly, (A) any shares of capital stock or securities convertible into capital stock of any other corporation or (B) any participating
interest in any partnership, joint venture or other non-corporate business enterprise or (ii) control, directly or indirectly, any other entity. 
 SECTION 2.2 Authorization of Agreements, Etc. 
 (a) The
execution and delivery by the Company of the Transaction Documents, the performance by the Company of its obligations thereunder, the issuance, sale and delivery of the Preferred Shares and the issuance and delivery of the ISB Shares, Warrants,
Conversion Shares and the Warrant Shares have been duly authorized by all requisite corporate action and will not violate any provision of law, any order of any court or other agency of government, the restated certificate of incorporation of the
Company (the “Charter”), or the bylaws of the Company (the “Bylaws”), or any provision of any indenture, agreement or other instrument to which the Company or any of its properties or assets is bound, or conflict
with, result in a breach of or constitute (with due notice or lapse of time or both) a default under any such indenture, agreement or other instrument, or result in the creation or imposition of any lien, charge, restriction, claim or encumbrance of
any nature whatsoever upon any of the properties or assets of the Company. 
 (b) The Preferred Shares have been
duly authorized and, when issued in accordance with this Agreement, will be validly issued, fully paid and nonassessable shares of Series A Preferred Stock with no personal liability attaching to the ownership thereof solely by virtue of the
acquisition thereof and will be free and clear of all liens, charges, restrictions, claims and encumbrances imposed by or through the Company except as set forth in the Investor Rights Agreement. The Conversion Shares have been duly reserved for
issuance upon conversion of the Preferred Shares and, when so issued, will be duly authorized, validly issued, fully paid and nonassessable shares of Common Stock with no personal liability attaching to the ownership thereof solely by virtue of the
acquisition thereof and will be free and clear of all liens, charges, restrictions, claims and encumbrances imposed by or through the Company except as set forth in the Investor Rights Agreement. The ISB Shares have been duly authorized and, when
issued in accordance with this Agreement, will be validly issued, fully paid and nonassessable shares of Common Stock with no personal liability attaching to the ownership thereof solely by virtue of the acquisition thereof and will be free and
clear of all liens, charges, restrictions, claims and encumbrances imposed by or through the Company except as set forth in the Investor Rights Agreement. The Warrants have been duly authorized and, when issued in accordance with this Agreement,
will be validly issued with no personal liability attaching to the ownership thereof solely by virtue of the acquisition thereof and will be free and clear of all liens, charges, restrictions, claims and encumbrances imposed by or through the
Company. The Warrant Shares have been duly reserved for issuance upon conversion of the Warrants and, when so issued upon exercise of the Warrants, will be duly authorized, validly issued, fully paid and nonassessable shares of Common Stock with no
personal liability attaching to the ownership 

  
 4 

 
thereof solely by virtue of the acquisition thereof and will be free and clear of all liens, charges, restrictions, claims and encumbrances imposed by or through the Company. Neither the
issuance, sale or delivery of the Preferred Shares, nor the issuance or delivery of the Conversion Shares, ISB Shares, Warrants or Warrant Shares, is subject to any preemptive right of stockholders of the Company or to any right of first refusal or
other right in favor of any person. 
 SECTION 2.3 Validity. This Agreement has been duly executed and delivered by the
Company and constitutes the legal, valid and binding obligation of the Company, enforceable in accordance with its terms (subject, as to the enforcement of remedies, to applicable bankruptcy, reorganization, insolvency, moratorium and similar laws
affecting creditors’ rights, and, with respect to the remedy of specific performance, equitable doctrines applicable thereto). The other Transaction Documents and the Warrants, when executed and delivered in accordance with this Agreement, will
constitute the legal, valid and binding obligations of the Company, enforceable in accordance with their respective terms (subject, as to the enforcement of remedies, to applicable bankruptcy, reorganization, insolvency, moratorium and similar laws
affecting creditors’ rights, and, with respect to the remedy of specific performance, equitable doctrines applicable thereto) and except to the extent the indemnification provisions contained in the Investor Rights Agreement may be limited by
applicable federal or state securities laws. 
 SECTION 2.4 Authorized Capital Stock. 

(a) The authorized capital stock of the Company consists of (i) 3,400,000 shares of preferred stock, par value $0.001
per share (the “Preferred Stock”), all of which have been designated Series A Preferred Stock, and (ii) 11,100,000 shares of Common Stock. Immediately prior to the Closing, 2,000,000 shares of Common Stock and no shares of
Series A Preferred Stock were issued and outstanding. As of the date hereof, (a) an aggregate of 3,400,000 shares of Common Stock is reserved for issuance and is issuable upon the conversion of authorized shares of the Series A Preferred Stock,
(b) an aggregate of 1,072,580 shares of Common Stock are reserved for issuance and are issuable upon the exercise of the Warrants, (c) an aggregate of 1,250,000 shares of Common Stock is reserved for issuance under the Company’s 2005
Stock Option Plan and (d) an aggregate of 583,571 shares of Common Stock are reserved for issuance and issuable upon the exercise of warrants and/or stock options issued to certain employees and consultants of the Company in connection with the
execution, delivery and performance of this Agreement. Immediately prior to the Closing, the stockholders of record and holders of subscriptions, warrants, options, convertible securities, and other rights (contingent or other) to purchase or
otherwise acquire equity securities of the Company, and the number of shares of Common Stock and the number of such subscriptions, warrants, options, convertible securities, and other such rights held by each, are as set forth in the attached
Schedule V. The designations, powers, preferences, rights, qualifications, limitations and restrictions in respect of each class and series of authorized capital stock of the Company are as set forth in the Charter, a copy of which is
attached as Exhibit F, and all such designations, powers, preferences, rights, qualifications, limitations and restrictions are valid, binding and enforceable and in accordance with all applicable laws. Except as set forth in the attached
Schedule V, (i) no person owns of record or is known to the Company to own beneficially any share of Common Stock, (ii) no subscription, warrant, option, convertible security, or other right (contingent or other) to purchase or
otherwise acquire equity securities of the Company is authorized or outstanding and (iii) there is no commitment by the Company to issue shares, 

  
 5 

 
subscriptions, warrants, options, convertible securities, or other such rights or to distribute to holders of any of its equity securities any evidence of indebtedness or asset. Except as
provided for in the Charter or as set forth in the attached Schedule V, the Company has no obligation (contingent or other) to purchase, redeem or otherwise acquire any of its equity securities or any interest therein or to pay any dividend
or make any other distribution in respect thereof. Except for this Agreement and the Stockholders Agreement, to the best of the Company’s knowledge, there are no voting trusts or agreements, stockholders’ agreements, pledge agreements,
buy-sell agreements, rights of first refusal, preemptive rights or proxies relating to any securities of the Company (whether or not the Company is a party thereto). All of the outstanding securities of the Company were issued in compliance with all
applicable Federal and state securities laws. 
 SECTION 2.5 Reserved. 

SECTION 2.6 Events Subsequent to the Incorporation. Since March 19, 2004, the date upon which the Company was incorporated in
the State of Delaware (the “Incorporation Date”), except as set forth in Section 2.6 of the Disclosure Schedule, the Company has not (i) issued any stock, bond or other corporate security, (ii) borrowed any amount or
incurred or become subject to any liability (absolute, accrued, contingent or anticipated), except current liabilities incurred and liabilities under contracts entered into in the ordinary course of business, (iii) discharged or satisfied any
lien or encumbrance or incurred or paid any obligation or liability (absolute, accrued, contingent or anticipated) other than current liabilities incurred since the date of the Incorporation Date in the ordinary course of business,
(iv) declared or made any payment or distribution to their stockholders or purchased or redeemed any interest or share of its capital stock or other security, (v) mortgaged, pledged, encumbered or subjected to lien any of their respective
assets, tangible or intangible, other than liens of current real property taxes not yet due and payable, (vi) sold, assigned or transferred any of their respective tangible assets except in the ordinary course of business, or canceled any debt
or claim, (vii) sold, assigned, transferred or granted any exclusive license with respect to any patent, trademark, trade name, service mark, copyright, trade secret or other intangible asset, (viii) suffered any loss of property or waived
any right of substantial value whether or not in the ordinary course of business, (ix) made any change in officer compensation except as expressly contemplated hereby, (x) made any material change in the manner of business or operations of
the Company, (xi) entered into any transaction except in the ordinary course of business or as otherwise contemplated hereby or (xii) entered into any commitment (contingent or otherwise) to do any of the foregoing. 

SECTION 2.7 Litigation; Compliance with Law. There is no (i) action, suit, claim, proceeding or investigation pending or, to
the best of the Company’s knowledge, threatened against or affecting the Company, at law or in equity, or before or by any Federal, state, municipal or other governmental department, commission, board, bureau, agency or instrumentality,
domestic or foreign, (ii) arbitration proceeding relating to the Company pending under collective bargaining agreements or otherwise or (iii) governmental inquiry pending or, to the best of the Company’s knowledge, threatened against
or affecting the Company (including without limitation any inquiry as to the qualification of the Company to hold or receive any license or permit), and to the best of the Company’s knowledge there is no basis for any of the foregoing. The
Company has not received any opinion or memorandum or legal advice from legal counsel to the effect that it is exposed, from a legal standpoint, to any liability or, 

  
 6 

 
disadvantage which may be material to its business, prospects, financial condition, operations, property or affairs. The Company is not subject to any order, writ, injunction or decree of any
court or of any Federal, state, municipal or other governmental department, commission, board, bureau, agency or instrumentality, domestic or foreign. There is no action or suit by the Company pending, threatened or contemplated against others. The
Company has complied with all laws, rules, regulations and orders applicable to its business, operations, properties, assets, products and services, the Company has all necessary permits, licenses and other authorizations required to conduct its
business as conducted and as proposed to be conducted, and the Company has been operating its business pursuant to and in compliance with the terms of all such permits, licenses and other authorizations. Except as set forth in Section 2.7 of
the Disclosure Schedule, there is no existing law, rule, regulation or order, and the Company after due inquiry is not aware of any proposed law, rule, regulation or order, whether Federal, state, county or local, which if complied with would
prohibit the Company from, or otherwise materially adversely affect the Company in, conducting its business in any jurisdiction in which it is now conducting business or in which it proposes to conduct business. 

SECTION 2.8 Proprietary Information of Third Parties. To the best of the Company’s knowledge, no third party has claimed or
has reason to claim that any person employed by or affiliated with the Company has (a) violated or may be violating any of the terms or conditions of such person’s employment, non-competition or non-disclosure agreement with such third
party, (b) disclosed or may be disclosing or utilized or may be utilizing any trade secret or proprietary information or documentation of such third party or (c) interfered or may be interfering in the employment relationship between such
third party and any of its present or former employees. No third party has requested information from the Company which suggests that such a claim might be contemplated. To the best of the Company’s knowledge, no person employed by or
affiliated with the Company has employed or proposes to employ any trade secret or any Intellectual Property (as defined below), information or documentation proprietary to any former employer, and to the best of the Company’s knowledge, no
person employed by or affiliated with the Company has violated or proposes to violate any confidential relationship which such person may have had with any third party, in connection with the development, manufacture or sale of any product or
proposed product or the development or sale of any service or proposed service of the Company, and the Company has no reason to believe there will be any such employment or violation. To the best of the Company’s knowledge, none of the
execution or delivery of this Agreement or the other Transaction Documents, or the carrying on of the business of the Company as officers, employees or agents by any officer, director or key employee of the Company, or the conduct or proposed
conduct of the business of the Company, will conflict with or result in a breach of the terms, conditions or provisions of or constitute a default under any contract, covenant or instrument under which any such person is obligated. 

SECTION 2.9 Patents, Trademarks, Etc. 
 (a) Set forth in Section 2.9(a) of the Disclosure Schedule is a list and brief description of all domestic and foreign patents, patent rights, patent applications, trademarks, trademark applications,
service marks, service mark applications, trade names and copyrights, and all applications for such which are in the process of being prepared, owned by or registered in the name of the Company, or of which the Company is a licensor or licensee or
in which the Company has any right, and in each case a brief description of the nature of such right. Except 

  
 7 

 
as set forth in Section 2.9(a) of the Disclosure Schedule, the Company owns or possesses adequate fully paid or perpetual licenses or other rights to use all patents, patent applications,
trademarks, trademark applications, service marks, service mark applications, trade names, copyrights, manufacturing processes, formulae, trade secrets, customer lists and know-how (collectively, “Intellectual Property”) necessary
or desirable to the conduct of its business as conducted and as proposed to be conducted, and no claim is pending or, to the best of the Company’s knowledge, threatened to the effect that the operations of the Company infringe upon or conflict
with the asserted rights of any other person under any Intellectual Property, and there is no basis for any such claim (whether or not pending or threatened). No claim is pending or, to the best of the Company’s knowledge, threatened to the
effect that any such Intellectual Property owned or licensed by the Company, or which the Company otherwise has the right to use, is invalid or unenforceable by the Company, and, to the best of the Company’s knowledge, there is no basis for any
such claim (whether or not pending or threatened). All prior art known to the Company which may be or may have been pertinent to the examination of any United States patent or patent application listed in Section 2.9(a) of the Disclosure
Schedule has been cited to the United States Patent and Trademark Office. The Company has entered into a written agreement with each past and present employee of the Company, consultant, advisor and independent contractor who may have or have had
access to the Intellectual Property that requires such employee, consultant, advisor and independent contractor to protect the confidentiality of all of the Intellectual Property, to not use any of the Intellectual Property other than on behalf of
the Company, and to assign to the Company all of such person’s right, title and interest with respect to all work and inventions relating to the Company or the Intellectual Property. The Company has taken reasonable precautions to maintain the
confidentiality of its trade secrets, know-how and other confidential Intellectual Property in connection with any disclosure to customers and potential customers of the Company who may have or have had access to such Intellectual Property. Except
as set forth in Section 2.9(a) of the Disclosure Schedule, the Company has not granted or assigned to any other person or entity any right to manufacture, have manufactured, assemble or sell the products or proposed products or to provide the
services or proposed services of the Company. 
 (b) Each Founder hereby confirms the prior assignment to the
Company of all right, title and interest, if any, in and to all rights of inventorship and authorship, rights in patents and patent applications, all copyrights, all trademark and service mark rights, all rights in trade secret and proprietary
information, all rights of attribution and integrity and other moral rights, and all other intellectual property rights of any type in so far as such intellectual property rights relate to such Founder’s collective or individual endeavors
regarding the Company’s products and services, as well as all other intellectual property rights relating thereto (collectively, the “Founder IP Rights”). Prior to the transfer of the Founder IP Rights to the Company by such
Founder, there was no claim pending or, to the best of each Founder’s knowledge, threatened to the effect that such Founder’s ownership or use of such Founder IP Rights infringed upon or conflicted with the asserted rights of any other
person. Prior to the transfer of the Founder IP Rights to the Company by such Founder, there was no claim pending or, to the best of such Founder’s knowledge, threatened to the effect that all or any portion of such Founder IP Rights were
invalid or unenforceable by such Founder. Each Founder has executed and delivered such instruments of sale, transfer, conveyance and assignment, and has taken such other action necessary to effectively sell, transfer, convey assign and deliver to,
and vest in, the Company, all right, title and interest in and to the Founder IP Rights. The Founder IP Rights represent all of 

  
 8 

 
the intellectual property at any time owned or licensed by each Founder which is necessary to the conduct of the Company’s business as presently conducted and proposed to be conducted. No
Founder has retained any ownership interest or license to any Intellectual Property necessary to the conduct of the Company’s business as presently conducted and proposed to be conducted. 

SECTION 2.10 Title to Properties. The Company has good, clear and marketable title to its respective properties and assets
acquired by it since the Incorporation Date, and all such properties and assets are free and clear of mortgages, pledges, security interests, liens, charges, claims, restrictions and other encumbrances (including without limitation, easements and
licenses), except for liens or current taxes not yet due and payable and minor imperfections of title, if any, not material in nature or amount and not materially detracting from the value or materially impairing the use of the property subject
thereto or materially impairing the operations or proposed operations of the Company, including, without limitation, the ability of the Company to secure financing using such properties and assets as collateral. To the best of the Company’s
knowledge, there are no condemnation, environmental, zoning or other land use regulation proceedings, either instituted or planned to be instituted, which would adversely affect the use or operation of the Company’s properties and assets for
their respective intended uses and purposes, or the value of such properties, and the Company has not received notice of any special assessment proceedings which would affect such properties and assets. 

SECTION 2.11 Leasehold Interests. Each lease or agreement to which the Company is a party under which it is a lessee of any
property, real or personal; is a valid and subsisting agreement, duly authorized and entered into, without any default of the Company thereunder. No event has occurred and is continuing which, with due notice or lapse of time or both, would
constitute a default or event of default by the Company under any such lease or agreement. The Company’s possession of such property has not been disturbed and, to the best of the Company’s knowledge after due inquiry, no claim has been
asserted against the Company adverse to its rights in such leasehold interests. 
 SECTION 2.12 Insurance. The Company
holds valid policies covering all of the insurance required to be maintained by it under Section 3.5 of the Investor Rights Agreement. 
 SECTION 2.13 Taxes. 
 (a) Except as set forth in
Section 2.13(a) of the Disclosure Schedule, the Company has timely filed all tax returns, Federal, state, county and local, required to be filed by it, and the Company has paid all taxes shown to be due by such returns as well as all other
taxes, assessments and governmental charges which have become due or payable, including without limitation all taxes which the Company is obligated to withhold from amounts owing to employees, creditors, independent contractors, shareholders and
third parties. All such tax returns were complete and correct in all material respects, and such tax returns correctly reflected the facts regarding the income, business, assets, operations, activities, status and other matters of the Company and
any other information required to be shown thereon. The Company has established adequate reserves for all taxes accrued but not yet payable. All tax elections of any type which the Company has made as of the date hereof are set forth on
Section 2.13(a) of the Disclosure Schedule. The Company has disclosed on its federal income tax returns all positions taken therein that could give rise to a substantial understatement of tax within the meaning of

  
 9 

 
Section 6662 of the Code (or any corresponding provision of state, local or foreign tax law). The Federal income tax returns of the Company have never been audited by the Internal Revenue
Service. No deficiency assessment with respect to or proposed adjustment of the Company’s Federal, state, county or local taxes is pending or, to the best of the Company’s knowledge, threatened. There is no tax lien (other than for current
real estate taxes not yet due and payable), whether imposed by any Federal, state, county or local taxing authority, outstanding against the assets, properties or business of the Company. Neither the Company nor any of its stockholders has ever
filed an election pursuant to Section 1362 of the Code that the Company be taxed as an S corporation. 
 (b)
The Company has not agreed or been required to make any adjustment under Section 481(a) of the Code (or any corresponding provision of state, local or foreign tax law) by reason of a change in accounting method or otherwise, and the Company
will not be required to make any such adjustment as a result of the transactions contemplated by this Agreement. The Company has never been a member of a group filing a consolidated federal income tax return or a combined, consolidated or other
affiliated group return for state tax purposes and the Company does not have any liability for the taxes of another person under Treasury Regulations Section 1.1502-6 (or any corresponding provision of state, local or foreign tax law) or as a
transferee or successor, by contract or otherwise. A valid and timely filed election under Section 83(b) of the Code has been made for all of the shares of the outstanding capital stock of the Company that are subject to a “substantial
risk of forfeiture” within the meaning of Section 83 of the Code. The Company has not been and is not a party to any tax sharing or similar agreement. Except as disclosed in Section 2.13(b) of the Disclosure Schedule, the Company has
never been, and is not, a party to any joint venture, partnership, limited liability company, or other arrangement or contract which could be treated as a partnership for federal income tax purposes. 

SECTION 2.14 Other Agreements. Except as set forth in Section 2.14 of the Disclosure Schedule and except for the Transaction
Documents, the Company is not a party to or otherwise bound by any written or oral agreement, instrument, commitment or restriction which individually or in the aggregate could materially adversely affect the business, prospects, financial
condition, operations, property or affairs of the Company or any other written or oral agreement with a third party, including but not limited to: 
 (a) distributor, dealer, manufacturer’s representative or sales agency agreement; 
 (b) sales agreement which entitles any customer to a rebate or right of set-off, to return any product to the Company after acceptance thereof or to delay the acceptance thereof, or which varies in any
material respect from the Company’s standard form agreements; 
 (c) agreement with any labor union (and, to
the knowledge of the Company, no organizational effort is being made with respect to any of its employees); 

(d) agreement with any supplier containing any provision permitting any party other than the Company to renegotiate the
price or other terms, or containing any pay-back or 

  
 10 

 
other similar provision, upon the occurrence of a failure by the Company to meet its obligations under the agreement when due or the occurrence of any other event; 

(e) agreement for the future purchase of fixed assets or for the future purchase of materials, supplies or equipment in
excess of the Company’s normal operating requirements; 
 (f) agreement for the employment or compensation
of any kind of any officer, employee or other person (whether of a legally binding nature or in the nature of informal understandings) on a full-time or consulting basis which is not terminable on notice without cost or other liability to the
Company, except accrued vacation pay; 
 (g) bonus, pension, profit-sharing, retirement, hospitalization,
insurance, stock purchase, stock option or other plan, agreement or understanding pursuant to which benefits are provided to any employee of the Company (other than group insurance plans which are not self-insured and are applicable to employees
generally); 
 (h) agreement relating to the borrowing of money or to the mortgaging or pledging of, or otherwise
placing a lien or security interest on, any asset of the Company; 
 (i) guarantee of any obligation for borrowed
money or otherwise; 
 (j) voting trust or agreement, stockholders’ agreement, pledge agreement, buy-sell
agreement or first refusal or preemptive rights agreement relating to any securities of the Company; 
 (k)
agreement, or group of related agreements with the same party or any group of affiliated parties, under which the Company has advanced or agreed to advance money or has agreed to lease any property as lessee or lessor; 

(l) agreement or obligation (contingent or otherwise) to issue, sell or otherwise distribute or to repurchase or otherwise
acquire or retire any share of its capital stock or any of its other equity securities; 
 (m) assignment,
license or other agreement with respect to any form of intangible property; 
 (n) agreement under which it has
granted any person any registration rights; 
 (o) agreement under which it has limited or restricted its right
to compete with any person in any respect; 
 (p) other agreement or group of related agreements with the same
party involving more than $10,000 or continuing over a period of more than six months from the date or dates thereof (including renewals or extensions optional with another party), which agreement or group of agreements is not terminable by the
Company without penalty upon notice of thirty (30) days or less, but excluding any agreement or group of agreements with a customer of the Company for the sale, lease or rental of the Company’s products or services if such agreement or
group of agreements was entered into by the Company in the ordinary course of business; or 

  
 11 

 (q) other agreement, instrument, commitment, plan or arrangement, a copy of
which would be required to be filed with the Securities and Exchange Commission (the “Commission”) as an exhibit to a registration statement on Form S-1 if the Company were registering securities under the Securities Act of 1933, as
amended (the “Securities Act”). 
 The Company, and to the best of the Company’s knowledge after due inquiry, each other
party thereto have in all material respects performed all the obligations required to be performed by them to date (or each non-performing party has received a valid, enforceable and irrevocable written waiver with respect to its non-performance),
have received no notice of default and are not in default (with due notice or lapse of time or both) under any agreement, instrument, commitment, plan or arrangement to which the Company is a party or by which it or its property may be bound. The
Company has no present expectation or intention of not fully performing all of its obligations under each such agreement, instrument, commitment, plan or arrangement, and the Company has no knowledge of any breach or anticipated breach by the other
party to any agreement, instrument, commitment, plan or arrangement to which the Company is a party. The Company is in full compliance with all of the terms and provisions of its Charter and Bylaws. 

SECTION 2.15 Loans and Advances. The Company does not have any outstanding loans or advances to any person and is not obligated to
make any such loans or advances, except, in each case, for advances to employees of the Company in respect of reimbursable business expenses anticipated to be incurred by them in connection with their performance of services for the Company.

 SECTION 2.16 Assumptions, Guaranties, Etc. of Indebtedness of Other Persons. The Company has not assumed, guaranteed,
endorsed or otherwise become directly or contingently liable on any indebtedness of any other person (including, without limitation, liability by way of agreement, contingent or otherwise, to purchase, to provide funds for payment, to supply funds
to or otherwise invest in the debtor, or otherwise to assure the creditor against loss), except for guaranties by endorsement of negotiable instruments for deposit or collection in the ordinary course of business. 

SECTION 2.17 Significant Customers and Suppliers. No customer or supplier which was significant to the Company during the period
from the Incorporation Date through the date hereof, has terminated, materially reduced or threatened to terminate or materially reduce its purchases from or provision of products or services to the Company, as the case may be. 

SECTION 2.18 Governmental Approvals. Subject to the accuracy of the representations and warranties of the Purchasers set forth in
Article III, no registration or filing with, or consent or approval of or other action by, any Federal, state or other governmental agency or instrumentality is or will be necessary for the valid execution, delivery and performance by the Company of
any of the Transaction Documents, the issuance, sale and delivery of the Preferred Shares or, upon conversion thereof, the issuance and delivery of the Conversion Shares, the issuance and delivery of the Warrants, or, upon exercise thereof, the
Warrant Shares, or the issuance or delivery of the ISB Shares, other than (i) filings pursuant to federal and state securities laws (all of which filings have been made by the Company, other than those which are required to be made after the
Closing and which will be duly made on a timely basis) in connection with the sale of the Preferred Shares and (ii) with respect to the Investor 

  
 12 

 
Rights Agreement, the registration of the shares covered thereby with the Commission and filings pursuant to state securities laws. 

SECTION 2.19 Disclosure. This Agreement, the other Transaction Documents and any Schedules (including, without limitation, the
Disclosure Schedule) and Exhibits to this Agreement or to the other Transaction Documents, all taken as a whole, do not contain an untrue statement of a material fact or omits a material fact necessary to make the statements contained herein or
therein not misleading. None of the statements, documents, certificates or other items prepared or supplied by the Company with respect to the transactions contemplated hereby contains an untrue statement of a material fact or omits a material fact
necessary to make the statements contained therein not misleading. There is no fact which the Company has not disclosed to the Investors and their respective counsels in writing of which the Company is aware which materially and adversely affects or
could materially and adversely affect the business, prospects, financial condition, operations, property or affairs of the Company. The financial projections and other estimates delivered to the Investors were prepared by the Company based on the
Company’s experience in the industry and on assumptions of fact and opinion as to future events which the Company, at the date of the issuance of such financial projections and estimates, believed to be reasonable, but which the Company cannot
and does not assure or guarantee the attainment of in any manner. As of the date hereof, no facts have come to the attention of the Company or any Founder which would, in its or his opinion, require the Company to revise or amplify the assumptions
underlying such projections and other estimates or the conclusions derived therefrom. 
 SECTION 2.20 Offering of the
Securities. Neither the Company nor any person authorized or employed by the Company as agent, broker, dealer or otherwise in connection with the offering or sale of the Preferred Shares, the ISB Shares, the Warrants or any security of the
Company similar to such securities has offered the Preferred Shares, the ISB Shares, the Warrants or any such similar securities for sale to, or solicited any offer to buy the Preferred Shares, the ISB Shares, the Warrants or any such similar
securities from, or otherwise approached or negotiated with respect thereto with, any person or persons, and neither the Company nor any person acting on its behalf has taken or will take any other action (including, without limitation, any offer,
issuance or sale of any security of the Company under circumstances which might require the integration of such security with Preferred Shares, the ISB Shares, or the Warrants under the Securities Act or the rules and regulations of the Commission
thereunder), in either case so as to subject the offering, issuance or sale of the Preferred Shares, the ISB Shares or the Warrants to the registration provisions of the Securities Act. 

SECTION 2.21 Brokers. The Company has no contract, arrangement or understanding with any broker, finder or similar agent with
respect to the transactions contemplated by this Agreement. 
 SECTION 2.22 Employees and Consultants. Set forth in
Section 2.22 of the Disclosure Schedule is a list of the names of the employees, consultants and other individuals receiving compensation from the Company, together with the title or job classification of each such person and the total
compensation anticipated to be paid to each such person by the Company in fiscal year 2005. Except as set forth in Section 2.22 of the Disclosure Schedule, 

  
 13 

 
none of such persons has an employment agreement or understanding, whether oral or written, with the Company, which is not terminable on notice by the Company without cost or other liability to
the Company. 
 SECTION 2.23 Transactions With Affiliates. No director, officer, employee or stockholder of the Company,
or member of the family of any such person, or any corporation, partnership, trust or other entity in which any such person, or any member of the family of any such person, has a substantial interest or is an officer, director, trustee, partner or
holder of more than 5% of the outstanding capital stock thereof, is a party to any transaction with the Company, including any contract, agreement or other arrangement providing for the employment of, furnishing of services by, rental of real or
personal property from or otherwise requiring payments to any such person or firm, other than employment-at-will arrangements in the ordinary course of business. 
 SECTION 2.24 Employees. Each of the officers of the Company, each key employee and each other employee now employed by the Company has executed a Proprietary Information and Inventions Assignment
Agreement in the form of Exhibit G (collectively, the “Employee Proprietary Information Agreements”), and such agreements are in full force and effect. No officer or key employee of the Company has advised the Company (orally
or in writing) that he intends to terminate employment with the Company. The Company has complied in all material respects with all applicable laws relating to the employment of labor, including provisions relating to wages, hours, equal
opportunity, collective bargaining and the payment of Social Security and other taxes. To the knowledge of the Company, no organizational effort regarding any labor union is being made with respect to any of its employees. 

SECTION 2.25 U.S. Real Property Holding Corporation. The Company is not now and has never been a “United States real property
holding corporation,” as defined in Section 897(c)(2) of the Code and Section 1.897-2(b) of the Regulations promulgated by the Internal Revenue Service, and the Company has filed with the Internal Revenue Service all statements, if
any, with its United States income tax returns which are required under Section 1.897-2(h) of such Regulations. 
 SECTION
2.26 Environmental Protection. The Company has not caused or allowed, or contracted with any party for, the generation, use, transportation, treatment, storage or disposal of any Hazardous Substances (as defined below) in connection with the
operation of its business or otherwise. The Company, the operation of its business, and any real property that the Company owns, leases or otherwise occupies or uses (the “Premises”) are in compliance with all applicable
Environmental Laws (as defined below) and orders or directives of any governmental authorities having jurisdiction under such Environmental Laws, including, without limitation, any Environmental Laws or orders or directives with respect to any
cleanup or remediation of any release or threat of release of Hazardous Substances. The Company has not received any citation, directive, letter or other communication, written or oral, or any notice of any proceeding, claim or lawsuit, from any
person arising out of the ownership or occupation of the Premises, or the conduct of its operations, and the Company is not aware of any basis therefor. The Company has obtained and is maintaining in full force and effect all necessary permits,
licenses and approvals required by all Environmental Laws applicable to the Premises and the business operations conducted thereon (including operations conducted by tenants on the 

  
 14 

 
Premises), and is in compliance with all such permits, licenses and approvals. The Company has not caused or allowed a release, or a threat of release, of any Hazardous Substance unto, at or near
the Premises, and, to the best of the Company’s knowledge, neither the Premises nor any property at or near the Premises has ever been subject to a release, or a threat of release, of any Hazardous Substance. For the purposes of this Agreement,
the term “Environmental Laws” shall mean any Federal, state or local law or ordinance or regulation pertaining to the protection of human health or the environment, including, without limitation, the Comprehensive Environmental
Response, Compensation and Liability Act, 42 U.S.C. Sections 9601, et seq., the Emergency Planning and Community Right-to-Know Act, 42 U.S.C. Sections 11001, et seq., and the Resource Conservation and Recovery Act, 42 U.S.C. Sections
6901, et seq. For purposes of this Agreement, the term “Hazardous Substances” shall include oil and petroleum products, asbestos, polychlorinated biphenyls, urea formaldehyde and any other materials classified as hazardous or
toxic under any Environmental Laws. 
 SECTION 2.27 ERISA. 

(a) Section 2.27(a) of the Disclosure Schedule lists each Employee Plan that covers any employee of the Company,
copies or descriptions of all of which have previously been made available or furnished to the Purchasers. With respect to each Employee Plan, the Company has provided the most recently filed Form 5500 and an accurate summary description of such
plan. The Company has provided the Purchasers with complete age, salary, service and related data as of the most recent practicable date for employees of the Company. 

(b) Section 2.27(b) of the Disclosure Schedule includes a list of each Benefit Arrangement of the Company, copies or
descriptions of all of which have been made available or furnished previously to the Purchasers. 
 (c) No
Employee Plan is a Multiemployer Plan and no Employee Plan is subject to Title IV of ERISA. The Company and its Affiliates have not incurred, nor do they expect to incur, any liability under Title IV of ERISA arising in connection with the
termination of any plan covered or previously covered by Title IV of ERISA. 
 (d) None of the Employee Plans or
other arrangements listed on Section 2.27(a) of the Disclosure Schedule covers any non-United States employee or former employee of the Company. 
 (e) No “prohibited transaction,” as defined in Section 406 of ERISA or Section 4975 of the Code, has occurred with respect to any Employee Plan. 

(f) Each Employee Plan which is intended to be qualified under Section 401(a) of the Code is so qualified and has
been so qualified during the period from its adoption to date, and each trust forming a part thereof is exempt from tax pursuant to Section 501(a) of the Code. The Company has furnished to the Purchasers copies of the most recent Internal
Revenue Service determination letters with respect to each such plan. Each Employee Plan has been maintained in compliance with its terms and with the requirements prescribed by any and all statutes, orders, rules and regulations, including but not
limited to ERISA and the Code, which are applicable to such plan. 

  
 15 

 (g) Each Benefit Arrangement has been maintained in substantial compliance
with its terms and with the requirements prescribed by any and all statutes, orders, rules and regulations which are applicable to such Employee Plan and Benefit Arrangement. 

(h) All contributions and payments accrued under each Employee Plan and Benefit Arrangement, determined in accordance with
prior funding and accrual practices, as adjusted to include proportional accruals for the period ending on the Closing Date, will be discharged and paid on or prior to the Closing Date. Except as disclosed in writing to the Purchasers prior to the
date hereof, there has been no amendment to, written interpretation of or announcement (whether or not written) by the Company or any of its ERISA Affiliates relating to, or change in employee participation or coverage under, any Employee Plan or
Benefit Arrangement that would increase materially the expense of maintaining such Employee Plan or Benefit Arrangement above the level of the expense incurred in respect thereof for the fiscal year ended prior to the date hereof. 

(i) There is no contract, agreement, plan or arrangement covering any employee or former employee of the Company that,
individually or collectively, could give rise to the payment of any amount that would not be deductible pursuant to the terms of Section 280G of the code. 
 (j) No tax under Section 4980B or 4980D of the Code has been incurred in respect of any Employee Plan that is a group health plan, as defined in Section 5000(b)(1) of the Code. 

(k) With respect to the employees and former employees of the Company, there are no employee post-retirement medical or
health plans in effect, except as required by Section 4980B of the Code. 
 (l) No employee of the Company
will become entitled to any bonus, retirement, severance or similar benefit or enhanced benefit solely as a result of the transactions contemplated hereby. 
 SECTION 2.28 Foreign Corrupt Practices Act. The Company has not taken any action which would cause it to be in violation of the Foreign Corrupt Practices Act of 1977, as amended, or any rules and
regulations thereunder. To the best of the Company’s knowledge after due inquiry, there is not now, and there has never been, any employment by the Company of, or beneficial ownership in the Company by, any governmental or political official in
any country in the world. 
 SECTION 2.29 Federal Reserve Regulations. The Company is not engaged in the business of
extending credit for the purpose of purchasing or carrying margin securities (within the meaning of Regulation G of the Board of Governors of the Federal Reserve System), and no part of the proceeds of the Preferred Shares will be used to purchase
or carry any margin security or to extend credit to others for the purpose of purchasing or carrying any margin security or in any other manner which would involve a violation of any of the regulations of the Board of Governors of the Federal
Reserve System. 

  
 16 

 ARTICLE III 
 REPRESENTATIONS AND WARRANTIES OF THE INVESTORS 
 Each Investor severally and not
jointly represents and warrants to the Company as follows: 
 SECTION 3.1 Authorization. Investor has the power and
authority to enter into the Transaction Documents. The Transaction Documents, when executed and delivered by Investor, will constitute legal, valid and binding obligations of Investor, enforceable in accordance with their respective terms (subject,
as to the enforcement of remedies, to applicable bankruptcy, reorganization, insolvency, moratorium and similar laws affecting creditors’ rights, and, with respect to the remedy of specific performance, equitable doctrines applicable thereto).

 SECTION 3.2 Accredited Investor. Investor is an “accredited investor” within the meaning of Rule 501 under
the Securities Act and was not organized for the specific purpose of acquiring the Preferred Shares, ISB Shares or Warrants, as the case may be. 
 SECTION 3.3 Experience; Purchase for Own Account. Investor has sufficient knowledge and experience in investing in companies similar to the Company in terms of the Company’s stage of
development so as to be able to evaluate the risks and merits of its investment in the Company and it is able financially to bear the risks thereof. The Preferred Shares, ISB Shares or Warrants, as the case may be, being purchased by Investor are
being acquired for its own account for the purpose of investment and not with a view to or for sale in connection with any distribution thereof. 
 SECTION 3.4 Access to Information. Investor has had an opportunity to discuss the Company’s business, management and financial affairs with the Company’s management and the conditions of
the offering of the Preferred Shares, the ISB Shares or Warrants, as applicable. 
 SECTION 3.5 No Public Market: Restricted
Shares. Investor understands that (i) the Preferred Shares, the Conversion Shares, the ISB Shares, the Warrants and the Warrant Shares, as the case may be, have not been registered under the Securities Act by reason of their issuance in a
transaction exempt from the registration requirements of the Securities Act pursuant to Section 4(2) thereof or Rule 505 or 506 promulgated under the Securities Act, (ii) the Preferred Shares and, upon conversion thereof, the Conversion
Shares, the ISB Shares and the Warrants, and upon exercise thereof, the Warrant Shares, as the case may be, must be held indefinitely unless a subsequent disposition thereof is registered under the Securities Act or is exempt from such registration,
(iii) the Preferred Shares, Conversion Shares, ISB Shares, Warrants and Warrant Shares will bear a legend to such effect and (iv) the Company will make a notation on its transfer books to such effect. If Investor sells any Conversion
Shares, ISB Shares or Warrant Shares, as the case may be, pursuant to Rule 144A promulgated under the Securities Act, it will take all necessary steps in order to perfect the exemption from registration provided thereby, including (i) obtaining
on behalf of the Company information to enable the Company to establish a reasonable belief that the purchaser is a qualified institutional buyer and (ii) advising such purchaser that Rule 144A is being relied upon with respect to such resale.

  
 17 

 SECTION 3.6 Legends. Investor understands that the Preferred Shares, the Conversion
Shares, the ISB Shares, Warrants and the Warrant Shares, as applicable, and any securities issued in respect of or exchange therefor, may bear one or all of the following legends: 

(i) “THE SECURITIES EVIDENCED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS
AMENDED (THE “SECURITIES ACT”), OR APPLICABLE STATE SECURITIES LAWS AND NO INTEREST IN THESE SECURITIES MAY BE SOLD, DISTRIBUTED, ASSIGNED, OFFERED, PLEDGED, OR OTHERWISE TRANSFERRED UNLESS (A) THERE IS AN EFFECTIVE REGISTRATION
STATEMENT UNDER THE SECURITIES ACT COVERING ANY SUCH TRANSACTION INVOLVING THESE SECURITIES, (B) THE COMPANY RECEIVES AN OPINION OF LEGAL COUNSEL IN A FORM REASONABLY SATISFACTORY TO THE COMPANY STATING THAT SUCH TRANSACTION IS EXEMPT FROM THE
REGISTRATION REQUIREMENTS OF THE SECURITIES ACT OR (C) THE COMPANY OTHERWISE SATISFIES ITSELF THAT SUCH TRANSACTION IS EXEMPT FROM THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT.” 

(ii) Any legend set forth in or required by the other Transaction Documents. 

(iii) Any legend required by the securities laws of any state to the extent such laws are applicable to the shares
represented by the certificate so legended. 
 SECTION 3.7 Brokers. Investor has no contract, arrangement or
understanding with any broker, finder or similar agent with respect to the transactions contemplated by this Agreement. 

ARTICLE IV 

CONDITIONS TO THE OBLIGATIONS OF THE INVESTORS 
 SECTION 4.1 Closing. The obligation of each Investor to purchase and pay for the ISB Shares, Warrants and Preferred Shares, as the case may be, being purchased by it on the Closing Date is, unless
waived by such Investor, subject to the satisfaction, on or before the Closing Date, of the following conditions: 
 (a) Opinion of Company’s Counsel. The Investors shall have received from Latham & Watkins LLP, counsel for the Company, an opinion dated as of the Closing Date, in substantially the
form attached hereto as Exhibit H. 
 (b) Representations and Warranties to be True and Correct.
The representations and warranties contained in Article II shall be true, complete and correct on and as of the Closing Date with the same effect as though such representations and warranties had been made on and as of such date, and the Chairperson
of the Company and each of the Founders shall have certified to such effect to the Investors in writing. 

  
 18 

 (c) Performance. The Company shall have performed and complied with
all agreements contained herein required to be performed or complied with by it prior to or at the Closing Date, and the Chairperson of the Company shall have certified to the Investors in writing to such effect and to the further effect that all of
the conditions set forth in this Article IV have been satisfied. 
 (d) All Proceedings to be
Satisfactory. All corporate and other proceedings to be taken by the Company in connection with the transactions contemplated hereby and all documents incident thereto shall be satisfactory in form and substance to the Investors and their
counsel, and the Investors and their counsel shall have received all such counterpart originals or certified or other copies of such documents as they reasonably may request. 

(e) Purchase by Other Purchasers. Each Purchaser (other than the Purchaser relying on this condition to excuse such
Purchaser’s performance hereunder) shall have purchased and paid for the Preferred Shares being purchased by it on the Closing Date, and the aggregate purchase price paid by all of the Purchasers for the Preferred Shares being purchased by them
on the Closing Date shall be $3,400,000. 
 (f) Supporting Documents. The Investors and their counsel
shall have received copies of the following documents: 
 (i) (A) the Charter, certified as of a recent date by
the Secretary of State of the State of Delaware; (B) a certificate of said Secretary dated as of a recent date as to the due incorporation and good standing of the Company (both corporate and tax), the payment of all excise taxes by the Company
and listing all documents of the Company on file with said Secretary; and (C) a certificate of the Secretary of State of Washington dated as of a recent date as to the good standing of the Company; and 

(ii) a certificate of the Secretary of the Company dated as of the Closing Date and certifying: (A) that attached
thereto is a true and complete copy of the Bylaws of the Company as in effect on the date of such certification; (B) that attached thereto is a true and complete copy of all resolutions adopted by the Board of Directors or the stockholders of
the Company authorizing the execution, delivery and performance of the Transaction Documents, the issuance, sale and delivery of the Preferred Shares and the reservation, issuance and delivery of the Conversion Shares, the issuance and delivery of
the ISB shares, the issuance and delivery of the Warrants, and the reservation, issuance and delivery of the Warrant Shares, and that all such resolutions are in full force and effect and are all the resolutions adopted in connection with the
transactions contemplated by the Transaction Documents; (C) that the Charter has not been amended since the date the Charter was originally filed; and (D) to the incumbency and specimen signature of each officer of the Company executing
any of the Transaction Documents, the stock certificates representing the Preferred Shares, the stock certificates representing the ISB Shares, the Warrants and any certificate or instrument furnished pursuant hereto. 

(g) Investor Rights Agreement. The Company shall have executed and delivered the Investor Rights Agreement.

  
 19 

 (h) Stockholders Agreement. The Stockholders Agreement shall have
been executed and delivered by the Company, each Purchaser (other than the Purchaser relying on this condition to exercise such Purchaser’s performance hereunder), each holder of Series A Preferred Stock and each holder of 1% or more of the
Company’s Common Stock. 
 (i) Charter. The Charter shall read in its entirety as set forth in
Exhibit F. 
 (j) Bylaws. The Company’s Bylaws shall have been amended, if necessary, to provide
for the matters set forth in Sections 3.11 and 3.12 of the Investor Rights Agreement. 
 (k) Employee
Proprietary Information Agreements. Copies of executed Employee Proprietary Information Agreements, substantially in the form attached as Exhibit G, shall have been delivered to counsel for the Investors. 

(l) Election of Directors. The number of directors constituting the entire Board of Directors shall have been fixed
at five (5), and the following persons shall have been elected as the directors and shall each hold such position as of the Closing Date: Ken Grabstein (“Grabstein”), Carl Weissman, Jay Hagan, Chad Waite and David Tirrell.

 (m) Fees of Investors’ Counsel. The Company shall have paid in accordance with Section 6.1
the fees and disbursements of Investors’ counsel invoiced at the Closing. 
 (n) Employment
Agreements. Each of Datta and Grabstein shall have entered into an Employment Agreement in substantially the form attached hereto as Exhibit I, and copies thereof shall have been delivered to counsel to the Investors. 

(o) Scientific Advisory Board Agreement. Each of Goddard and Tirrell shall have entered into a Scientific Advisory
Board Agreement with the Company in substantially the form attached hereto as Exhibit J and copies thereof shall have been delivered to counsel to the Investors. 

(p) Stock Restriction Agreements. Each of Datta, Goddard and Tirrell shall have entered into Stock Restriction
Agreements with the Company in substantially the form attached hereto as Exhibit E, and copies thereof shall have been delivered to counsel to the Investors. 

(q) Management Rights. A Management Rights Letter with each Purchaser who shall so request in the form set forth in
Exhibit K duly executed and delivered by the Company. 
 (r) License Agreement. The Company shall
have entered into a License Agreement with the California Institute of Technology in substantially the form attached hereto as Exhibit L, a copy of which shall have been delivered to counsel to the Investors. 

All such documents shall be satisfactory in form and substance to the Investors and their counsel. 

  
 20 

 ARTICLE V 
 INDEMNIFICATION 
 SECTION 5.1 Company Indemnification. 

(a) The Company agrees to indemnify, defend and hold harmless the Investors, their respective affiliates and their
respective officers, directors, trustees, agents, employees, partners and controlling persons (each, an “Indemnified Party”) against any and all Losses (as hereinafter defined) including, without limitation, Losses arising out of or
relating to any legal, administrative or other actions (including actions brought by the Investors or the Company or any equity holders of the Company or derivative actions brought by any person claiming through or in the Company’s name),
proceedings or investigations (whether formal or informal), or written threats thereof, based upon, resulting from, relating to or arising out of this Agreement, each of the other Transaction Documents, any breach of any representation, warranty,
covenant or agreement by the Company in this Agreement or the other Transaction Documents, the transactions contemplated hereby and thereby, or any Indemnified Party’s role therein or in transactions contemplated hereby or thereby;
provided, that if and to the extent that such indemnification is unenforceable for any reason, the Company shall make the maximum contribution to the payment and satisfaction of such Losses which shall be permissible under applicable laws.

 (b) In connection with the Company’s indemnification obligations as set forth in Section 5.1(a)
above, the Company shall, upon presentation of appropriate invoices containing reasonable detail, reimburse each Indemnified Party for all such expenses (including reasonable expenses of investigation and reasonable fees, disbursements and other
charges of counsel in connection with any claim, action, suit or proceeding) as they are incurred by such Indemnified Party. 
 (c) For purposes of this Article V, the term “Losses” means all losses, claims (including any claim by a third party), damages, expenses (including reasonable fees, disbursements and
other charges of counsel incurred by the Indemnified Party in connection with any claim, action, suit or proceeding including any action between the Indemnified Party and the Company or between the Indemnified Party and any third party or otherwise)
or other liabilities. 
 SECTION 5.2 Founders’ Acknowledgement. Each Founder acknowledges and agrees that such
Founder shall not have and shall not exercise or assert any right of contribution, indemnification, subrogation or other remedy or right against the Company in connection with any breaches of the representations and warranties set forth in
Section 2.9(b) hereof. 
 SECTION 5.3 Investor Rights Agreement. Notwithstanding anything to the contrary contained
in this Article V, the indemnification and contribution provisions of the Investor Rights Agreement shall govern any claim made with respect to registration statements filed pursuant thereto or sales made thereunder. 

  
 21 

 ARTICLE VI 
 MISCELLANEOUS 
 SECTION 6.1 Expenses. Each party hereto will pay its own
expenses in connection with the transactions contemplated hereby, provided, however, that the Company shall pay the fees and disbursements of the Investors’ special counsel, Goodwin Procter, LLP, such fees and disbursements not to exceed
$55,000, and in connection with such transactions and any subsequent amendment, waiver, consent or enforcement thereof. 

SECTION 6.2 Transfer Taxes. Any transfer, documentary, stamp, or other similar taxes assessed upon or with the issuance, sale and
delivery of the Preferred Shares, ISB Shares or Warrants, pursuant to this Agreement, and any recording or filing fees with respect thereto, shall be the responsibility of the Company. 

SECTION 6.3 Acknowledgement. Any investigation or other examination that may have been made at any time by or on behalf of a party
to whom representations and warranties are made in this Agreement or in any other Transaction Documents shall not limit, diminish, supersede, act as a waiver of, or in any other way affect the representations, warranties and indemnities contained in
this Agreement and the other Transaction Documents, and the respective parties may rely on the representations, warranties and indemnities made to them in this Agreement and the other Transaction Documents irrespective of and notwithstanding any
information obtained by them in the course of any investigation, examination or otherwise, whether before or after the Closing. 

SECTION 6.4 Survival of Agreements. All covenants, agreements, representations and warranties made in this Agreement or any
certificate or instrument delivered to the Investors pursuant to or in connection with this Agreement, shall survive the execution and delivery of all of this Agreement, the issuance, sale and delivery of the Preferred Shares, and the issuance and
delivery of the Conversion Shares, ISB Shares, Warrants and Warrant Shares, and all statements contained in any certificate or other instrument delivered by the Company hereunder or in connection herewith shall be deemed to constitute
representations and warranties made by the Company. 
 SECTION 6.5 Brokerage. Each party hereto will indemnify and hold
harmless the others against and in respect of any claim for brokerage or other commissions relative to this Agreement or to the transactions contemplated hereby, based in any way on agreements, arrangements or understandings made or claimed to have
been made by such party with any third party. 
 SECTION 6.6 Parties in Interest. All representations, covenants and
agreements contained in this Agreement by or on behalf of any of the parties hereto shall bind and inure to the benefit of the respective successors and assigns of the parties hereto whether so expressed or not. Without limiting the generality of
the foregoing, all representations, covenants and agreements benefiting the Investors shall inure to the benefit of any and all subsequent holders from time to time of Preferred Shares, Conversion Shares, ISB Shares, Warrants or Warrant Shares.

  
 22 

 SECTION 6.7 Notices. All notices, requests, consents and other communications
hereunder shall be in writing and shall be delivered in person, mailed by certified or registered mail, return receipt requested, or sent by overnight courier, telecopier or telex, addressed as follows: 

(a) if to the Company, at Allozyne, Inc. Attention: President, 1616 Eastlake Avenue East, Seattle, Washington 98102, with
a copy to Latham & Watkins LLP, 633 West Fifth Street, Suite 4000, Los Angeles, CA 90071, Attention: Edward Sonnenschein, Jr., Esq., telecopier number (213) 891-8763; 

(b) if to any Purchaser, at the address of such Purchaser set forth in Schedule I, with a copy to Goodwin Procter
LLP, Exchange Place, Boston, Massachusetts 02109, Attention: Mitchell S. Bloom, Esq., telecopier number (617) 523-1231; 
 (c) if to ISB, at the address set forth in Schedule H; and 

(d) if to Accelerator, at the address set forth in Schedule III, with a copy to Goodwin Procter LLP, Exchange
Place, Boston, Massachusetts 02109, Attention: Mitchell S. Bloom, Esq., telecopier number (617) 523-1231; 
 or, in any such case, at such
other address or addresses as shall have been furnished in writing by such party to the others. 
 SECTION 6.8 Governing
Law. This Agreement shall be governed by and construed in accordance with the laws of the State of New York, without giving effect to the principles of conflicts of laws thereof. 

SECTION 6.9 Entire Agreement. This Agreement and the other Transaction Documents, including the schedules and exhibits hereto and
thereto, constitute the sole and entire agreement, and supersede all prior agreements and understandings, of the parties with respect to the subject matter hereof. All Schedules and Exhibits hereto are hereby incorporated herein by reference.

 SECTION 6.10 Counterparts. This Agreement may be executed in more than one counterpart, each of which shall be deemed
to be an original, and which, together, shall constitute one and the same instrument. This Agreement, to the extent signed and delivered by means of a facsimile machine or electronic mail in .pdf file format, will be treated in all manner and
respects as an original agreement and will be considered to have the same binding legal effect as if it were the original signed version thereof delivered in person. 
 SECTION 6.11 Amendment and Waiver. 
 (a) Except as otherwise
expressly provided herein, this Agreement may be amended of modified only upon the written consent of the Company and the Purchasers holding at least a majority of the outstanding shares of Series A Preferred Stock held by all Purchasers
provided that no such amendment or modification which, by its express terms, is (1) applicable to a particular Purchaser and (2) not applicable to all other Purchasers in a like or similar manner shall be binding as to such
Purchaser unless such Purchaser consents in writing to such 

  
 23 

 
amendment or modification. Any such amendment or modification effected in accordance with this Section 6.11(a) shall be binding on all parties hereto, even if they do not execute such
consent. 
 (b) Subject to Section 6.1.1(c) below, any party hereto may waive compliance with any
agreements, covenants or conditions for the benefit of such party contained herein. Any agreement on the part of a party hereto to any such waiver shall be valid only if set forth in an instrument in writing signed on behalf of such party.

 (c) Except as otherwise expressly provided herein, the obligations of the Company and the rights of the
Purchasers under this Agreement may be waived with respect to all parties to this Agreement (either generally or in a particular instance and either retroactively or prospectively) only with the written consent of the Purchasers holding at least a
majority of the Series A Preferred Stock held by all Purchasers provided that no such waiver which, by its express terms, is (1) applicable to a particular Purchaser and (2) not applicable to all other Purchasers in a like or
similar manner shall be binding as to such Purchaser unless such Purchaser consents in writing to such waiver. Any such waiver effected in accordance with this Section 6.11(c) shall be binding on all parties hereto, even if they do not execute
such consent. 
 SECTION 6.12 Severability. If any provision of this Agreement shall be declared void or unenforceable by
any judicial or administrative authority, the validity or enforceability of any other provision and of the entire Agreement shall not be affected thereby. 
 SECTION 6.13 Titles and Subtitles. The titles and subtitles used in this Agreement are for convenience only and are not to be considered in construing or interpreting any term or provision of this
Agreement. 
 SECTION 6.14 Pronouns. Whenever the context may require, any pronouns used in this Agreement shall include
the corresponding masculine, feminine or neuter form, and the singular form of nouns and pronouns shall include the plural, and vice versa. 
 SECTION 6.15 Certain Defined Terms. As used in this Agreement, the following terms shall have the following meanings (such meanings to be equally applicable to both the singular and plural forms of
the terms defined): 
 (a) “Benefit Arrangement” means each employment, severance or other
similar contract, arrangement or policy (written or oral) and each plan or arrangement (written or oral) providing for severance benefits, insurance coverage (including any self-insured arrangements), workers’ compensation, disability benefits,
supplemental unemployment benefits, vacation benefits, retirement benefits or for deferred compensation, profit-sharing, bonuses, stock options, stock appreciation rights or other forms of incentive compensation or post-retirement insurance,
compensation or benefits which (i) is not an Employee Plan and (ii) covers any employee or former employee of the Company. 
 (b) “Employee Plan” means each “employee benefit plan,” as such term is defined in Section 3(3) of ERISA, that (A)(i) is subject to any provision of ERISA and (ii) is
maintained or contributed to by the Company, or (B)(i) is subject to any provision of Title IV of ERISA and (ii) is maintained or contributed to by any of the Company’s ERISA Affiliates. 

  
 24 

 (c) “ERISA” means the Employee Retirement Income Security
Act of 1974, as amended. 
 (d) “ERISA Affiliate” of any entity means any other entity that,
together with such entity, would be treated as a single employer under Section 414 of the Code. 
 (e)
“knowledge” means, (i) with respect to the Company, the knowledge of the operating management of the Company (including, without the limitation, each Founder) and shall be deemed to include the knowledge of facts which should
reasonably be known or knowable by persons acting in such capacity and (ii) with respect to each of the Founders, the knowledge of such Founder and shall be deemed to include the knowledge of facts which should reasonably be known or knowable
after reasonable investigation. 
 (f) “Multiemplover Plan” means each Employee Plan that is a
multiemployer plan, as defined in Section 3(37) of ERISA. 
 (g) “person” shall mean an
individual, corporation, trust, partnership, joint venture, unincorporated organization, government agency or any agency or political subdivision thereof, or other entity. 

(h) “subsidiary” shall mean, as to the Company, any corporation of which more than 50% of the outstanding
stock having ordinary voting power to elect a majority of the board of directors of such corporation (irrespective of whether or not at the time stock of any other class or classes of such corporation shall have or might have voting power by reason
of the happening of any contingency) is at the time directly or indirectly owned by the Company, or by one or more of its subsidiaries, or by the Company and one or more of its subsidiaries. 

SECTION 6.16 Aggregation of Affiliated Purchasers. For the purposes of applying all provisions of this Agreement which condition
the receipt of information or access to information or exercise of any rights upon ownership of a specified number or percentage of shares, the shares owned of record by any affiliate (as hereinafter defined) of a Purchaser shall be deemed to be
owned by such Purchaser. For purposes of this Agreement, the term “affiliate” shall mean, with respect to any person, any other person, directly or indirectly, controlling, controlled by or under common control with such person.

 SECTION 6.17 Waiver of Conflicts. Each party to this Agreement acknowledges that Latham & Watkins LLP,
counsel for the Company, has in the past performed and may continue to perform legal services for certain of the Investors in matters unrelated to the transactions described in the Transaction Documents, including the representation of such
Investors in venture capital financings and other matters. Accordingly, each party to this Agreement hereby (a) acknowledges that they have had an opportunity to ask for information relevant to this disclosure; and (b) gives its informed
consent to Latham & Watkins LLP’s representation of the Company in connection with this Agreement and the transactions contemplated hereby, subject to any additional agreements which have been entered into between Latham &
Watkins LLP and such party. 
 SECTION 6.18 Electronic Delivery of Stockholder Notices. Each of the Investors consents to
the delivery to it by the Company of all future notices and other communications to 

  
 25 

 
shareholders by e-mail to the address set forth below and/or by facsimile transmission to the number set forth below. Each of the Investors understands that it may revoke this consent at any time
by giving notice to the Company. 
 SECTION 6.19 Publicity. No party hereto may, nor may it permit its Affiliates to,
issue or cause the publication of any press release or other public announcement with respect to this Agreement or the transactions contemplated hereby and the other Transaction Documents without the prior consent of the Company and the Purchasers.
Notwithstanding the foregoing, (i) any party may disclose the existence of this Agreement and the other. Transaction Documents and the general terms and conditions of this Agreement and the other Transaction Documents to any person as
reasonably required in the course of private business discussions with such person; (ii) each of Alexandria Accelerator LLC (“Alexandria”) and Amgen Ventures LLC (“Amgen”) shall have the right to review any
proposed public release of information disclosing any information related to the existence or the terms and conditions of this Agreement and the other Transaction Documents; and (iii) each of Alexandria and Amgen shall have the right to have
their respective name deleted from any such public release of information regarding the Company, this Agreement and the other Transaction Documents. 
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK] 

  
 26 

 SCHEDULE I 
 PURCHASERS 
  

							
	 Name and Address,

Fax and Email of Purchaser
	  	
Number of Preferred
Shares to be Purchased
	  	 Aggregate 
Purchase Price for
Preferred
Shares

	 ARCH Venture Fund V, L.P.
 8725 W. Higgins Road
 Suite 290
 Chicago, IL 60631
	  	570,825	  	$570,825
	Fax:	 	(773) 380-6606	  		  	
	Attn:	 	Mark McDonnell	  		  	
		 	Robert T. Nelsen	  		  	
	Email:	 	mmcdonnell@archventure.com	  		  	
		 	rtn@archventure.com	  		  	
			
	 ARCH V Entrepreneurs Fund, L.P.
 8725 W. Higgins Road
 Suite 290
 Chicago, IL 60631
	  	3,792	  	$3,792
	Fax:	 	(773) 380-6606	  		  	
	Attn:	 	Mark McDonnell	  		  	
		 	Robert T. Nelsen	  		  	
	Email:	 	mmcdonnell@archventure.com	  		  	
		 	rtn@archventure.com	  		  	
			
	 MPM BioVentures III, L.P.
 111 Huntington Ave., 31st Floor
 Boston, MA 02199
	  	64,156	  	$64,156
	Fax:	 	(617) 425-9201	  		  	
	Attn:	 	Rob Liptak	  		  	
		 	Lauren Fiore	  		  	
		 	Michael Steinmetz	  		  	
	Email: 	 	rliptak@mpmcapital.com	  		  	
		 	lfiore@mpmcapital.com	  		  	
		 	msteinmetz@mpmcapital.com	  		  	
			
	 MPM BioVentures III-QP, L.P.
 1l1 Huntington Ave., 31st Floor
 Boston, MA 02199
	  	954,170	  	$954,170
	Fax:	 	(617) 425-9201	  		  	
	Attn:	 	Rob Liptak	  		  	
		 	Lauren Fiore	  		  	
		 	Michael Steinmetz	  		  	
	Email: 	 	rliptak@mpmcapital.com	  		  	
		 	lfiore@mpmcapital.com	  		  	
		 	msteinmetz@mpmcapital.com	  		  	

							
	 Name and Address,

Fax and Email of Purchaser
	  	Number of Preferred
Shares to be Purchased	  	Aggregate 
Purchase Price for
Preferred Shares
	 MPM BioVentures III GmbH & Co.
 Beteiligungs KG
 111 Huntington Ave., 31” Floor

Boston, MA 02199
	  	80,639	  	$80,639
	Fax:	 	(617) 425-9201	  		  	
	Attn:	 	Rob Liptak	  		  	
		 	Lauren Fiore	  		  	
		 	Michael Steinmetz	  		  	
	Email:	 	rliptak@mpmcapital.com	  		  	
		 	lfiore@mpmcapital.com	  		  	
		 	msteinmetz@mpmcapital.com	  		  	
			
	 MPM BioVentures III Parallel Fund, L.P.
 111 Huntington Ave., 31st Floor
 Boston, MA 02199
	  	28,816	  	$28,816
	Fax:	 	(617) 425-9201	  		  	
	Attn:	 	Rob Liptak	  		  	
		 	Lauren Fiore	  		  	
		 	Michael Steinmetz	  		  	
	Email: 	 	rliptak@mpmcapital.com	  		  	
		 	lfiore@mpmcapital.com	  		  	
		 	msteinmetz@mpmcapital.com	  		  	
			
	 MPM Asset Management Investors 2003
 BVIII LLC
 111 Huntington Ave., 31st Floor

Boston, MA 02199
	  	18,474	  	$18,474
	Fax:	 	(617) 425-9201	  		  	
	Attn:	 	Rob Liptak	  		  	
		 	Lauren Fiore	  		  	
		 	Michael Steinmetz	  		  	
	Email:	 	rliptak@mpmcapital.com	  		  	
		 	lfiore@mpmcapital.com	  		  	
		 	msteinmetz@mpmcapital.com	  		  	
			
	 Alexandria Accelerator LLC
 135 North Los Robles Avenue
 Suite 250
 Pasadena, CA 91101
	  	171,938	  	$171,938
	Fax:	 	(626) 578-0770	  		  	
	Attn:	 	Joel Marcus	  		  	
	Email:	 	jmarcus@labspace.com	  		  	
			
	 Amgen Ventures LLC

One Amgen Center Drive
 Thousand Oaks, CA
91320-1799
 Attention: Joseph Hagan,
	  	753,595	  	$753,595

  
 2 

							
	 Name and Address,

Fax and Email of Purchaser
	  	
Number of Preferred
Shares to be Purchased
	  	 Aggregate 
Purchase Price for
Preferred
Shares

	Managing Director	  		  	
	Fax:	 	(805) 480-9892	  		  	
	Email:	 	jhagan@amgen.com	  		  	
			
	 OVP Venture Partners VI, L.P.
 c/o OVP Venture Partners
 1010 Market Street

Kirkland, WA 98033
	  	738,523	  	$738,523
	Attn:	 	Bill Funcannon	  		  	
	Fax:	 	(425) 889-0152	  		  	
	Email:	 	funcannon@ovp.com	  		  	
		 	waite@ovp.com	  		  	
			
	 OVP VI Entrepreneurs Fund, L.P.
 c/o OVP Venture Partners
 1010 Market Street

Kirkland, WA 98033
	  	15,072	  	$15,072
	Attn:	 	Bill Funcannon	  		  	
	Fax:	 	(425) 889-0152	  		  	
	Email:	 	funcannon@ovp.com	  		  	
		 	waite@ovp.com	  		  	
		 		  	  
	  	  

	Total:	 		  	3,400,000	  	$3,400,000

  
 3 

 SCHEDULE II 

 

							
	 Name and Address,

Fax and Email
	  	 Number of Shares of
Common
Stock
	  	 Aggregate 
Purchase Price for
ISB
Shares

	 Institute for Systems Biology
 1441 North
34th Street

Seattle, WA 98103-8904
	  	858,065	  	$8,580.65
	Fax:	 	(206) 732-1260	  		  	
	Attn:	 	Lee Hood	  		  	
		 	Louis Coffman	  		  	
	Email:	 	lhood@systemsbiology.org	  		  	
		 	lcoffman@systemsbiology.org	  		  	

 SCHEDULE III 

 

					
	 Name and Address, 
Fax and Email
	  	
Warrants to
Purchase Common Stock

	 ISB Accelerator Corporation
 1616 Eastlake Ave. E.
 Seattle, WA 98102
	  	643,548
	Fax:	 	(206) 957-7399	  	
	Attn:	 	Carl Weissman	  	
		 	Lindsay Rayle	  	
	Email:	 	cweissman@acceleratorcorp.com	  	
		 	lrayle@acceleratorcorp.com	  	
		
	 ISB Accelerator Corporation
 1616 Eastlake Ave. E.
 Seattle, WA 98102
	  	429,032
	Fax:	 	(206) 957-7399	  	
	Attn:	 	Carl Weissman	  	
		 	Lindsay Rayle	  	
	Email:	 	cweissman@acceleratorcorp.com	  	
		 	lrayle@acceleratorcorp.comSERIES B CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT

 Exhibit 10.51 
 Execution Version 
 SERIES B CONVERTIBLE PREFERRED STOCK PURCHASE
AGREEMENT 
 THIS SERIES B CONVERTIBLE PREFERRED STOCK PURCHASE AGREEMENT (the “Agreement”) is made as of
the 22nd day of October, 2007 by and among Allozyne, Inc., a Delaware corporation (the “Company”), and the investors listed on Exhibit A attached to this Agreement (each a “Purchaser” and together the
“Purchasers”). 
 The parties hereby agree as follows; 

1. Purchase and Sale of Preferred Stock. 
 1.1 Sale and Issuance of Series B Preferred Stock. 
 (a) The
Company shall adopt and file with the Secretary of State of the State of Delaware on or before the First Closing (as defined below) the Second Amended and Restated Certificate of Incorporation in the form of Exhibit B attached to this
Agreement (the “Restated Certificate”). 
 (b) Subject to the terms and conditions of this
Agreement, each Purchaser agrees to purchase at each Closing (as defined below) and the Company agrees to sell and issue to each Purchaser at the Closing that number of shares of Series B-1 Convertible Preferred Stock, par value $0.001 (the
“Series B-1 Preferred Stock”), or Series B-2 Convertible Preferred Stock, par value $0.001 (the “Series B-2 Preferred” and together with the Series B-1 Preferred Stock the “Series B Preferred
Stock”) set forth opposite each Purchasers name on Exhibit A, at a purchase price of $1.00 per share of Series B-1 Preferred Stock and at the Second Closing Purchase Price per share of Series B-2 Preferred Stock. The shares of Series
B Preferred Stock issued to the Purchasers pursuant to this Agreement (including any shares issued at the First Closing (the “Initial Shares”) and any Milestone Shares (as defined below) shall be referred to in this Agreement as the
“Shares.” 
 1.2 Closing; Delivery. 

(a) The purchase and sale of the Initial Shares shall take place remotely via the exchange of documents and signatures, at
12:00 p.m., on October 22, 2007, or at such other time and place as the Company and the Purchasers mutually agree upon, orally or in writing (which time and place are designated as the “First Closing”). In the event there is
more than one closing, the term “Closing” shall apply to each such closing unless otherwise specified. 
 (b) At each Closing, the Company shall deliver to each Purchaser a certificate representing the Shares being purchased by such Purchaser at such Closing against payment of the purchase price therefor by
check payable to the Company by wire transfer to a bank account designated by the Company, or by any combination of such methods. 

 1.3 Sale of Milestone Shares of Preferred Stock. 

(a) After the First Closing, the Company shall sell, and the Purchasers shall purchase, severally and not jointly, on the
same terms and conditions as those contained in this Agreement, up to 12,000,000 shares of Series B-2 Preferred Stock (the “Milestone Shares”), pro rata in accordance with the number of shares of Series B-1 Preferred
Stock being purchased by each such Purchaser at the First Closing, on the good faith determination by a majority of the Company’s Board of Directors (the “Board”) (which majority must include at least three out of four of the
members of the Board designated by the holders of Preferred Stock) that the events described on Annex I have occurred within the time frames set forth therein (the “Milestone Events”). The date of the purchase and sale of the
Milestone Shares are referred to in this Agreement as the “Second Closing.” Notwithstanding the foregoing, if the Company fails to achieve the Milestone Events on or before March 31, 2009, then the Purchasers holding a majority
of the Series B-1 Preferred Stock then held by all Purchasers (a “Majority Interest”) may, no later than April 15, 2009, waive in writing any such failure and cause all Purchasers to make the investment contemplated by this
Section 1.3. If no such written waiver is delivered to the Company and all Purchasers by April 15, 2009, then the obligations of the Company and the Purchasers under this Section 1.3 shall be null and void and without
any further legal force or effect. 
 (b) Subject to the satisfaction or waiver of the conditions precedent set
forth in Section 4(b) hereof relating to the Second Closing, the Second Closing shall occur no later than fifteen (15) business days after the date on which the Milestone Events have been achieved (as determined in accordance with
Section 1.3(a)) or a Majority Interest has voted to proceed with the investment associated with the Second Closing (as contemplated by Section 1.3(a)), and, in connection with the Second Closing, the Purchasers and the
Company shall work in good faith to establish the date, time and other particulars pertaining to such closing (including, without limitation, the execution and delivery of the items to be delivered to the Purchasers at the Second Closing pursuant to
Section 4(b) hereof). 
 (c) If any Purchaser fails to purchase such Purchaser’s allocable
portion of Series B-2 Preferred Stock issued at the Second Closing (as provided in Section 1.3(a) above), then all shares of Series B-1 Preferred Stock then held by such Purchaser shall be automatically converted into shares of the
Company’s Common Stock, par value $0.001 (the “Common Stock”), as contemplated by the Restated Certificate. 
 1.4 Use of Proceeds. In accordance with the directions of the Board, the Company will use the proceeds from the sale of the Shares for product development and other general corporate purposes.

 1.5 Defined Terms Used in this Agreement. In addition to the terms defined above, the following terms
used in this Agreement shall be construed to have the meanings set forth or referenced below. 

“Affiliate” means, with respect to any specified Person, any other Person who or which, directly or
indirectly, controls, is controlled by, or is under common control with such specified Person, including, without limitation, any partner, officer, director, member or employee of such Person and any venture capital fund now or hereafter existing
that is controlled by or under common control with one or more general partners or managing members of, or shares the same management company with, such Person. 

  
 2 

 “Code” means the Internal Revenue Code of 1986, as amended.

 “Company Intellectual Property” means all patents, patent applications, trademarks, trademark
applications, service marks, service mark applications, tradenames, copyrights, trade secrets, domain names, mask works, information and proprietary rights and processes, similar or other intellectual property rights, subject matter of any of the
foregoing, tangible embodiments of any of the foregoing, licenses in to and under any of the foregoing, in any and all such cases that are owned by the Company or used, or proposed to be used, by the Company in the conduct of the Company’s
business as now conducted and as presently proposed to be conducted, it being understood that where any activity or product of the Company would constitute an infringement or misappropriation of a patent or other intellectual property right if not
done by the owner of such patent or other intellectual property right, or its licensee, such patent or other intellectual property right will be considered “used” by the Company for purposes of this definition. 

“Investor Rights Agreement” means the Amended and Restated Investor Rights Agreement between the Company,
the Purchasers and the other parties thereto dated as of the date of the First Closing, In the form of Exhibit E attached to this Agreement. 
 “Key Employee” means Meenua Chhabra and Kenneth Grabstein. 
 “Knowledge,” including the phrase “to the Company’s knowledge,” shall, subject to the last sentence of Section 2.8, mean the actual knowledge of each Key
Employee and that knowledge which a Key Employee could have obtained through reasonable inquiries of any other personnel of the Company or from a reasonable review of materials or documents of the Company available to the Key Employee. 

“Management Rights Letter” means the agreement between the Company and a Purchaser, dated as of the date
of the First Closing, in the form of Exhibit F attached to this Agreement. 
 “Material Adverse
Effect” means a material adverse effect on the business, assets (including intangible assets), liabilities, financial condition, property or results of operations of the Company. 

“Person” means any individual, corporation, partnership, trust, limited liability company, association or
other entity. 
 “Preferred Stock” means the Company’s Series A Convertible Preferred
Stock, par value $0.001 (the “Series A Preferred Stock”), and the Series B Preferred Stock. 

“Second Closing Purchase Price” means (i) if the Company achieves the Milestone Events on or prior
to March 31, 2009, $1.10 or (ii) if the Company fails to achieve the Milestone Events on or prior to March 31, 2009, but the Majority Interest waives such failure as contemplated by Section 1.3(a), $1.00. 

  
 3 

 “Securities Act” means the Securities Act of 1933, as
amended, and the rules and regulations promulgated thereunder. 
 “Shares” means the Initial
Shares issued at the First Closing and any Milestone Shares issued at a subsequent Closing under Section 1.3. 
 “Stockholders Agreement” means the Amended and Restated Stockholders Agreement among the Company, the Purchasers, and certain other stockholders of the Company, dated as of the date of
the First Closing, in the form of Exhibit G attached to this Agreement. 
 “Transaction
Agreement” means this Agreement, the Investor Rights Agreement and the Stockholders Agreement. 
 2. Representations
and Warranties of the Company. The Company hereby represents and warrants to each Purchaser that, except as set forth on the Disclosure Schedule attached as Exhibit C to this Agreement (the “Disclosure Schedule”) which
exceptions shall be deemed to be part of the representations and warranties made hereunder, the following representations are true and complete as of the date of the First Closing, except as otherwise indicated. The Disclosure Schedule shall be
arranged in sections corresponding to the numbered and lettered sections and subsections contained in this Section 2, and the disclosures in any section or subsection of the Disclosure Schedule shall qualify other sections and
subsections in this Section 2 only to the extent it is reasonably apparent from a reading of the disclosure that such disclosure is applicable to such other sections and subsections. 

For purposes of these representations and warranties (other than those in Sections 2.2, 2.3, 2.4,
2.5 and 2.6) the term “Company” shall Include any subsidiaries of the Company, unless otherwise noted herein. 
 2.1 Organization, Good Standing, Corporate Power and Qualification. The Company is a corporation duly organized, validly existing and in good standing under the laws of the State of Delaware and
has all requisite corporate power and authority to carry on its business as presently conducted and as proposed to be conducted. The Company is duly qualified to transact business and is in good standing in each jurisdiction in which the failure to
so qualify would have a Material Adverse Effect. 
 2.2 Capitalization. All of the outstanding securities
of the Company have been duly authorized, are fully paid and nonassessable and were issued in compliance with all applicable federal and state securities laws. The Company holds no treasury Stock and no shares of Preferred Stock in its treasury. The
authorized capital of the Company consists, immediately prior to the First Closing, of: 
 (a) 55,000,000 shares
of Common Stock, 2,445,565 shares of which are issued and outstanding immediately prior to the First Closing. 

  
 4 

 (b) 36,801,499 shares of Preferred Stock, of which 6,801,499 shares have
been designated Series A Preferred Stock, 6,492,999 of which are issued and outstanding immediately prior to the First Closing, of which 18,000,000 shares have been designated Series B-1 Preferred Stock, none of which are issued and outstanding
immediately prior to the First Closing and 12,000,000 of which have been designated Series B-2 Preferred Stock, none of which are issued and outstanding immediately prior to the First Closing. The rights, privileges and preferences of the Preferred
Stock are as stated in the Restated Certificate and as provided by the general corporation law of the jurisdiction of the Company’s Incorporation. 
 (c) The Company has reserved 7,237,292 shares of Common Stock for issuance to officers, directors, employees and consultants of the Company pursuant to its 2005 Stock Option Plan duly adopted by the Board
and approved by the Company stockholders (the “Stock Plan”). Of such reserved shares of Common Stock, options to purchase 970,000 shares have been granted and are currently outstanding, and 6,267,292 shares of Common Stock remain
available for issuance to officers, directors, employees and consultants pursuant to the Stock Plan. The Company has furnished to the Purchasers complete and accurate copies of the Stock Plan and forms of agreements used thereunder. 

(d) Section 2.2(d) of the Disclosure Schedule sets forth the capitalization of the Company immediately
following the First Closing including the number of shares of the following: (i) issued and outstanding Common Stock, including, with respect to restricted Common Stock, vesting schedule and repurchase price; (ii) issued stock options;
(iii) stock options not yet issued but reserved for Issuance, including vesting schedule and exercise price; (iv) each series of Preferred Stock; and (v) warrants or stock purchase rights, if any. Except for (A) the conversion
privileges of the Shares to be issued under this Agreement and (B) the securities and rights described in Section 2.2(c) of this Agreement and Section 2.2(d) of the Disclosure Schedule, there are no outstanding options,
warrants, rights (including conversion or preemptive rights and rights of first refusal or similar rights) or agreements, orally or in writing, to purchase or acquire from the Company any shares of Common Stock or Preferred Stock, or any securities
convertible into or exchangeable for shares of Common Stock or Preferred Stock. All outstanding shares of the Company’s Common Stock and all shares of the Company’s Common Stock underlying outstanding options are subject to (i) a
right of first refusal in favor of the Company upon any proposed transfer (other than transfers for estate planning purposes); and a lock-up or market standoff agreement of not less than one hundred eighty (180) days following the
Company’s initial public offering pursuant to a registration statement filed with the Securities and Exchange Commission under the Securities Act. 
 (e) The Company is under no obligation, including, but not limited to, under its stock purchase agreements or stock option documents, to accelerate vesting (or lapse a repurchase right) or make other
changes in the vesting provisions or other terms of any agreement or understanding upon the occurrence of any event or combination of events. The Company has never adjusted or amended the exercise price of any stock options previously awarded,
whether through amendment, cancellation, replacement grant, repricing, or any other means. Except as set forth in the Restated Certificate, the Company has no obligation (contingent or otherwise) to purchase or redeem any of its capital stock.

  
 5 

 2.3 Subsidiaries. The Company does not currently own or control,
directly or indirectly, any interest in any other corporation, partnership, trust, joint venture, limited liability company, association, or other business entity. The Company is not a participant in any joint venture, partnership or similar
arrangement. 
 2.4 Authorization. All corporate action required to be taken by the Board and stockholders
in order to authorize the Company to enter into the Transaction Agreements, and to issue the Shares at the Closing and the Common Stock issuable upon conversion of the Shares, has been taken or will be taken prior to the Closing. All action on the
part of the officers of the Company necessary for the execution and delivery of the Transaction Agreements, the performance of all obligations of the Company under the Transaction Agreements to be performed as of the Closing, and the issuance and
delivery of the Shares has been taken or will be taken prior to the Closing. The Transaction Agreements, when executed and delivered by the Company, shall constitute valid and legally binding obligations of the Company, enforceable against the
Company in accordance with their respective terms except (i) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, or other laws of general application relating to or affecting the enforcement of
creditors’ rights generally, (ii) as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies, or (iii) to the extent the indemnification provisions contained in the
Investors’ Rights Agreement and the Indemnification Agreement may be limited by applicable federal or state securities laws. 
 2.5 Valid Issuance of Shares. The Shares, when issued, sold and delivered in accordance with the terms and for the consideration set forth in this Agreement, will be validly issued, fully paid and
nonassessable and free of restrictions on transfer other than restrictions on transfer under the Transaction Agreements, applicable state and federal securities laws and liens or encumbrances created by or imposed by a Purchaser. Assuming the
accuracy of the representations of the Purchasers in Section 3 of this Agreement and subject to the filings described in Section 2.6(ii) below, the Shares will be issued in compliance with all applicable federal and state
securities laws. The Common Stock issuable upon conversion of the Shares has been duly reserved for issuance, and upon issuance in accordance with the terms of the Restated Certificate, will be validly issued, fully paid and nonassessable and free
of restrictions on transfer other than restrictions on transfer under the Transaction Agreements, applicable federal and state securities laws and liens or encumbrances created by or imposed by a Purchaser. Based in part upon the representations of
the Purchasers in Section 3 of this Agreement, and subject to Section 2.6 below, the Common Stock issuable upon conversion of the Shares will be issued in compliance with all applicable federal and state securities laws.

 2.6 Governmental Consents and Filings. Assuming the accuracy of the representations made by the
Purchasers in Section 3 of this Agreement, no consent, approval, order or authorization of, or registration, qualification, designation, declaration or filing with, any federal, state or local governmental authority is required on the
part of the Company in connection with the consummation of the transactions contemplated by this Agreement, except for (i) the filing of the Restated Certificate, which will have been filed as of the First Closing, and (ii) filings
pursuant to Regulation D of the Securities Act, and applicable state securities laws, which have been made or will be made in a timely manner. 

  
 6 

 2.7 Litigation. There is no claim, action, suit, proceeding,
arbitration, complaint, charge or investigation pending, or to the Company’s knowledge, currently threatened in writing, against the Company or any officer, director or Key Employee of the Company. Neither the Company nor, to the Company’s
knowledge, any of its officers or directors, is a party or is named as subject to the provisions of any order, writ, injunction, judgment or decree of any court or government agency or instrumentality (in the case of officers or directors, such as
would affect the Company). The foregoing includes, without limitation, actions, suits, proceedings or investigations pending or threatened in writing (or any basis therefor known to the Company) involving the prior employment of any of the
Company’s employees, their services provided in connection with the Company’s business, or any information or techniques allegedly proprietary to any of their former employers, or their obligations under any agreements with prior
employers. There is no action, suit, proceeding or investigation by the Company pending or which the Company intends to initiate. 
 2.8 Intellectual Property. The Company exclusively owns all Company Intellectual Property that it purports to own and, to the knowledge of the Company, possesses sufficient and enforceable legal
rights to such Company Intellectual Property as necessary for the operation of the Company’s business as now conducted and as presently proposed to be conducted and, to the knowledge of the Company, possesses sufficient and enforceable legal
rights to all Company Intellectual Property licensed to the Company as necessary for the operation of the Company’s business as now conducted and as presently proposed to be conducted, and without any conflict with, or infringement of, the
rights of others. Neither any activity by the Company, nor the manufacture, use, importation, offer for sale and/or sale of any product or service marketed or sold (or proposed to be marketed or sold) by the Company infringes or violates (or in the
past infringed or violated) the rights of any others in or to any intellectual property rights (“Third Party Intellectual Property”), other than the rights of any person or entity under any patent, or constitutes a misappropriation
(or in the past constituted a misappropriation of) any subject matter of any Third Party Intellectual Property and, to the Company’s knowledge, neither any activity by the Company, nor the manufacture, use, importation, offer for sale and/or
sale of any product or service marketed or sold (or proposed to be marketed or sold) by the Company infringes or violates (or in the past infringed or violated) the rights of any others in or to any patent. The Company has, and to the knowledge of
the Company each other party to any and all licenses of Third Party Intellectual Property to the Company have, performed in all material respects their material obligations under all such licenses, and neither the Company nor, to the knowledge of
the Company, any other party thereto is in default thereunder. Other than with respect to commercially available software products under standard end-user object code license agreements each of which is made available for a total cost of less than
82,000, there are no outstanding options. licenses, agreements, pledges, claims, charges, security interests, encumbrances or shared ownership interests of any kind relating to the Company Intellectual Property, nor is the Company bound by or a
party to any options, licenses or agreements of any kind with respect to any patents, trademarks, service marks, trade names, copyrights, trade secrets, licenses, information, proprietary rights or processes of any other Person. The Company has not
received any written communications alleging that the Company has violated or, by conducting the Company’s business as now conducted and as presently proposed to be conducted, should be licensed under or would otherwise violate any of the
patents, trademarks, service marks, tradenames, copyrights, trade secrets, mask works or other proprietary or intellectual property rights or processes of any other 

  
 7 

 
Person. The Company has obtained and possesses valid licenses to use all of the software programs present on the computers and other software-enabled electronic devices that it owns or leases or
that it has otherwise provided to its employees for their use in connection with the Company’s business as now conducted and as presently proposed to be conducted. To the Company’s knowledge, it will not be necessary to use any inventions
of any of its employees or consultants (or persons it currently intends to hire) made prior to their employment by the Company. Each employee and consultant has assigned to the Company all intellectual property rights he or she owns that are related
to the Company’s business as now conducted and as presently proposed to be conducted. Section 2.8 of the Disclosure Schedule lists all Company Intellectual Property consisting of patents, patent applications and registered and
material unregistered trademarks, service marks and copyrights. The Company has taken reasonable security measures to protect the secrecy, confidentiality and value of all trade secrets, know-how and other confidential and proprietary information
owned by the Company or used by the Company in the Company’s business as now conducted and as presently proposed to be conducted. For purposes of this Section 2.8, the Company shall be deemed to have knowledge of a patent right if
the Company has actual knowledge of the patent right or would be found to be on notice of such patent right as determined by reference to United States patent laws. 

2.9 Compliance with Other Instruments. The Company is not in violation or default (i) of any provisions of its
Restated Certificate or bylaws, (ii) of any instrument, judgment, order, writ or decree, (iii) under any note, indenture or mortgage, or (iv) under any lease, agreement, contract or purchase order to which it is a party or by which it
is bound that is required to be listed on the Disclosure Schedule, or, to its knowledge, of any provision of federal or state statute, rule or regulation applicable to the Company, the violation of which would have a Material Adverse Effect. The
execution, delivery and performance of the Transaction Agreements and the consummation of the transactions contemplated by the Transaction Agreements will not result in any such violation or be in conflict with or constitute, with or without the
passage of time and giving of notice. either (x) a default under any such provision, instrument, judgment, order, writ, decree, contract or agreement or (y) an event which results in the creation of any lien, charge or encumbrance upon any
assets of the Company or the suspension, revocation, forfeiture, or nonrenewal of any material permit or license applicable to the Company. 
 2.10 Agreements; Actions. 
 (a) Except for the Transaction
Agreements and those disclosed on Section 2.10(a) of the Disclosure Schedules, there are no agreements, understandings, instruments, contracts or proposed transactions to which the Company is a party or by which it is bound that involve
(i) obligations (contingent or otherwise) of, or payments to, the Company in excess of $20,000, (ii) the license of any patent, copyright, trademark, trade secret or other proprietary right to or from the Company, (iii) the grant of
rights to manufacture, produce, assemble, license, market, or sell its products to any other Person that limit the Company’s exclusive right to develop, manufacture, assemble, distribute, market or sell its products, or
(iv) indemnification by the Company with respect to infringements of proprietary rights. 

  
 8 

 (b) Except as disclosed in Section 2.10(b) of the Disclosure
Schedules, the Company has not (i) claimed or paid any dividends, or authorized or made any distribution upon or with respect to any class or series of its capital stock, (ii) incurred any indebtedness for money borrowed or incurred
any other liabilities individually in excess of $20,000 or in excess of $50,000 in the aggregate, (iii) made any loans or advances to any Person, other than ordinary advances for travel expenses, or (iv) sold, exchanged or otherwise
disposed of any of its assets or rights, other than the sale of its inventory in the ordinary course of business. For the purposes of Section 2.10(b) and 2.10(c), all indebtedness, liabilities, agreements, understandings,
instruments, contracts and proposed transactions involving the same Person (including Persons the Company has reason to believe are affiliated with each other) shall be aggregated for the purpose of meeting the individual minimum dollar amounts of
such subsection. 
 (c) The Company is not a guarantor or indemnitor of any indebtedness of any other Person.

 2.11 Certain Transactions. 

(a) Other than (i) standard employee benefits generally made available to all employees, (ii) standard director
and officer indemnification agreements approved by the Board, and (iii) the purchase of shares of the Company’s capital stock and the issuance of options to purchase shares of the Company’s Common Stock, in each instance, approved in
the written minutes of the Board (previously provided to the Purchasers or their counsel), there are no agreements, understandings or proposed transactions between the Company and any of its officers, directors, consultants or Key Employees, or any
Affiliate thereof. 
 (b) The Company is not indebted, directly or indirectly, to any of its directors, officers
or employees or to their respective spouses or children or to any Affiliate of any of the foregoing, other than in connection with expenses or advances of expenses incurred in the ordinary course of business or employee relocation expenses and for
other customary employee benefits made generally available to all employees. None of the Company’s directors, officers or employees, or any members of their immediate families, or any Affiliate of the foregoing (i) are, directly or
indirectly, indebted to the Company or, (ii) to the Company’s knowledge, have any direct or indirect ownership interest in any firm or corporation with which the Company is affiliated or with which the Company has a business relationship,
or any firm or corporation which competes with the Company except that directors, officers or employees or stockholders of the Company may own stock in (but not exceeding two percent (2%) of the outstanding capital stock of) publicly traded
companies that may compete with the Company. To the Company’s knowledge, none of the Company’s Key Employees or any members of their immediate families or any Affiliate of any of the foregoing are, directly or indirectly, interested in any
material contract with the Company. None of the Company’s officers, or any members of their immediate families, has any material commercial, industrial, banking, consulting, legal, accounting, charitable or familial relationship with any of the
Company’s customers, suppliers, service providers, joint venture partners, licensees and competitors. 

2.12 Bights of Registration and Voting Rights. Except as provided in the Investor Rights Agreement, the Company is
not under any obligation to register under the Securities Act any of its currently outstanding securities or any securities issuable upon exercise or conversion of its currently outstanding securities. To the Company’s knowledge, except as
contemplated in the Stockholders Agreement, no stockholder of the Company has entered into any agreements with respect to the voting of capital shares of the Company. 

  
 9 

 2.13 Absence of Liens. The property and assets that the Company owns
are free and clear of all mortgages, deeds of trust, liens, loans and encumbrances, except for statutory liens for the payment of current taxes that are not yet delinquent and encumbrances and liens that arise in the ordinary course of business and
do not materially impair the Company’s ownership or use of such property or assets. With respect to the property and assets it leases, the Company is in compliance with such leases and, to its knowledge, holds a valid leasehold interest free of
any liens, claims or encumbrances other than those of the lessors of such property or assets. 
 2.14
Financial Statements. The Company has delivered to each Purchaser its audited financial statements as of December 31, 2006 and for the fiscal year then ended and its unaudited financial statements (including balance sheet, income
statement and statement of cash flows) as of August 31, 2007 and for the eight-month period ended August 31, 2007 (collectively the “Financial Statements”). The Financial Statements have been prepared in accordance with
generally accepted accounting principles in the United States (“GAAP”) applied on a consistent basis throughout the periods indicated, except that the unaudited Financial Statements may not contain all footnotes required by GAAP.
The Financial Statements fairly present in all material respects the financial condition and operating results of the Company as of the dates, and for the periods, indicated therein, subject in the case of the unaudited Financial Statements to
normal year-end audit adjustments. Except as set forth in the Financial Statements, the Company has no material liabilities or obligations, contingent or otherwise, other than (i) liabilities incurred in the ordinary course of business
subsequent to August 31, 2007 (ii) obligations under contracts and commitments incurred in the ordinary course of business and (iii) liabilities and obligations of a type or nature not required under generally accepted accounting
principles to be reflected in the Financial Statements, which, in all such cases, individually and in the aggregate would not have a Material Adverse Effect. The Company maintains and will continue to maintain a standard system of accounting
established and administered in accordance with GAAP. 
 2.15 Changes. Since August 31, 2007, there
has not been: 
 (a) any change in the assets, liabilities, financial condition or operating results of the
Company from that reflected in the Financial Statements, except changes in the ordinary course of business that have not caused, in the aggregate, a Material Adverse Effect; 

(b) any damage, destruction or loss, whether or not covered by insurance, that would have a Material Adverse Effect;

 (c) any waiver or compromise by the Company of a valuable right or of a material debt owed to it; 

(d) any satisfaction or discharge of any lien, claim, or encumbrance or payment of any obligation by the Company, except
in the ordinary course of business and the satisfaction or discharge of which would not have a Material Adverse Effect; 
 (e) any material change to a material contract or agreement by which the Company or any of its assets is bound or subject; 

  
 10 

 (f) any material change in any compensation arrangement or agreement with
any employee, officer, director or stockholder; 
 (g) any resignation or termination of employment of any
officer or Key Employee of the Company; 
 (h) any mortgage, pledge, transfer of a security interest in, or lien,
created by the Company, with respect to any of its material properties or assets, except liens for taxes not yet due or payable and liens that arise in the ordinary course of business and do not materially impair the Company’s ownership or use
of such property or assets; 
 (i) any loans or guarantees made by the Company to or for the benefit of its
employees, officers or directors, or any members of their immediate families, other than travel advances and other advances made in the ordinary, course of its business; 

(j) any declaration, setting aside or payment or other distribution in respect of any of the Company’s capital stock,
or any direct or indirect redemption, purchase, or other acquisition of any of such stock by the Company; 
 (k)
any sale, assignment or transfer of any Company Intellectual Property that could reasonably be expected to result in a Material Adverse Effect; 
 (l) receipt of notice that there has been a loss of, or material order cancellation by any major customer of the Company; 

(m) to the Company’s knowledge, any other event or condition of any character, other than events affecting the
economy or the Company’s industry generally, that could reasonably be expected to result in a Material Adverse Effect; or 
 (n) any arrangement or commitment by the Company to do any of the things described in this Section 2.15. 

2.16 Employee Matters. 
 (a) As of the date hereof, the Company employs nine (9) full-time employees and one (1) part-time employees and engages approximately five (5) consultants or independent contractors.
Section 2.16(a) of the Disclosure Schedule sets forth a detailed description of all compensation, including salary, bonus, severance obligations and deferred compensation paid or payable for each officer, employee, consultant and
independent contractor of the Company who received compensation in excess of $150,000 for the fiscal year ended December 31, 2006 or is anticipated to receive compensation in excess of $150,000 for the fiscal year ending December 31, 2007.

 (b) To the Company’s knowledge, none of its employees is obligated under any contract (including
licenses, covenants or commitments of any nature) or other agreement, or subject to any judgment, decree or order of any court or administrative agency, that would materially interfere with such employee’s ability to promote the interest of the
Company or that would conflict with the Company’s business. Neither the execution or delivery 

  
 11 

 
of the Transaction Agreements, nor the carrying on of the Company’s business by the employees of the Company, nor the conduct of the Company’s business as now conducted and as presently
proposed to be conducted, will, to the Company’s knowledge, conflict with or result in a breach of the terms, conditions, or provisions of, or constitute a default under, any contract, covenant or instrument under which any such employee is now
obligated. 
 (c) The Company is not delinquent in payments to any of its employees, consultants, or independent
contractors for any wages, salaries, commissions, bonuses, or other direct compensation for any service performed for it to the date hereof or amounts required to be reimbursed to such employees, consultants, or independent contractors. The Company
has complied in all material respects with all applicable state and federal equal employment opportunity laws and with other laws related to employment, including those related to wages, hours, worker classification, and collective bargaining. The
Company has withheld and paid to the appropriate governmental entity or is holding for payment not yet due to such governmental entity all amounts required to be withheld from employees of the Company and is not liable for any arrears of wages,
taxes, penalties, or other sums for failure to comply with any of the foregoing. 
 (d) To the Company’s
knowledge, no Key Employee intends to terminate employment with the Company or is otherwise likely to become unavailable to continue as a Key Employee, nor does the Company have a present intention to terminate the employment of any of the
foregoing. The employment of each employee of the Company is terminable at the will of the Company. Except as set forth in Section 2.16(d) of the Disclosure Schedule or as required by law, upon termination of the employment of any such
employees, no severance or other payments will become due. Except as set forth in Section 2.16(d) of the Disclosure Schedule, the Company has no policy, practice, plan, or program of paying severance pay or any form of severance
compensation in connection with the termination of employment services. 
 (e) The Company has not made any
representations regarding equity incentives to any officer, employees, director or consultant that are inconsistent with the share amounts and terms set forth in the Company’s board minutes. 

(f) Each former Key Employee whose employment was terminated by the Company has entered into an agreement with the Company
providing for the full release of any claims against the Company or any related party arising out of such employment. 
 (g) Section 2.16(g) of the Disclosure Schedule sets forth each employee benefit plan maintained, established or sponsored by the Company, or which the Company participates in or contributes
to, which is subject to the Employee Retirement Income Security Act of 1974, as amended (“ERISA”). The Company has made all required contributions on a timely basis and has complied in all material respects with all applicable laws
for any such employee benefit plan. The Company does not maintain any retiree health or life plans providing for continuing coverage or benefits for any employee after the employees termination of employment, except to the extent such coverage is
required by Part 6 of Title I(B) of ERISA. 

  
 12 

 (h) To the Company’s knowledge, none of the Key Employees or directors
of the Company has been (i) subject to voluntary or involuntary petition under the federal bankruptcy laws or any state insolvency law or the appointment of a receiver, fiscal agent or similar officer by a court for his business or property;
(ii) convicted in a criminal proceeding or named as a subject of a pending criminal proceeding (excluding traffic violations and other minor offenses); (iii) subject to any order, judgment, or decree (not subsequently reversed, suspended,
or vacated) of any court of competent jurisdiction permanently or temporarily enjoining him from engaging, or otherwise imposing limits or conditions on his engagement in any securities, investment advisory, banking, insurance, or other type of
business or acting as an officer or director of a public company; or (iv) found by a court of competent jurisdiction in a civil action or by the Securities and Exchange Commission or the Commodity Futures Trading Commission to have violated any
federal or state securities, commodities, or unfair trade practices law, which such judgment or finding has not been subsequently reversed, suspended, or vacated. 

2.17 Tax Returns and Payments. There are no federal, state, county, local or foreign taxes due and payable by the
Company which have not been timely paid, There are no accrued and unpaid federal, state, country, local or foreign taxes of the Company which are due, whether or not assessed or disputed. There have been no examinations or audits of any tax returns
or reports by any applicable federal, state, local or foreign governmental agency. The Company has duly and timely filed all federal, state, county, local and foreign tax returns required to have been filed by it and there are in effect no waivers
of applicable statutes of limitations with respect to taxes for any year. 
 2.18 Insurance. The Company
has in full force and effect fire and casualty insurance policies with extended coverage, sufficient in amount (subject to reasonable deductions) to allow it to replace any of its properties that might be damaged or destroyed. 

2.19 Confidential Information and Invention Assignment Agreements. Each current and former employee, consultant and
officer of the Company has executed an agreement with the Company regarding confidentiality and proprietary information in a form that was approved by the Board (the “Confidential Information Agreements”). No current or former Key
Employee has excluded works or inventions from his or her assignment of inventions pursuant to such Key Employee’s Confidential Information Agreement. The Company is not aware that any of its Key Employees is in violation thereof. Copies of all
such agreements have been provided to the Purchasers. 
 2.20 Permits. The Company and each of its
subsidiaries has all franchises, permits, licenses and any similar authority necessary for the conduct of its business, the lack of which could reasonably be expected to have a Material Adverse Effect. The Company is not in default in any material
respect under any of such franchises, permits, licenses or other similar authority. 
 2.21 Corporate
Documents. The Restated Certificate and bylaws of the Company are in the form provided to the Purchasers. The copy of the minute books of the Company provided to the Purchasers contains minutes of all meetings of directors and stockholders and
all actions by written consent without a meeting by the directors and stockholders since the dale of incorporation and accurately reflects in all material respects all actions by the director’s (and any committee of directors) and stockholders
with respect to all transactions referred to in such minutes. 

  
 13 

 2.22 Real Property Holding Corporation. The Company is not now and
has never been a “United States real property holding corporation” as defined in the Code and any applicable regulations promulgated thereunder. The Company has filed with the Internal Revenue Service all statements, if any, with its
United States income tax returns which are required under such regulations. 
 2.23 Environmental and Safety
Laws. 
 (a) Except as could not reasonably be expected to have a Material Adverse Effect to the best of its
knowledge (i) the Company is and has been in compliance with all Environmental Laws; (ii) there has been no release or to the Company’s knowledge threatened release of any pollutant, contaminant or toxic or hazardous material,
substance or waste, or petroleum or any fraction thereof, (each a “Hazardous Substance”) on upon into or from any site currently or heretofore owned, leased or otherwise used by the Company; (iii) there have been no Hazardous
Substances generated by the Company that have been disposed of or come to rest at any site that has been included in any published U.S. federal, state or local “superfund” site list or any other similar list of hazardous or toxic waste
sites published by any governmental authority in the United States; and (d) there are no underground storage tanks located on, no polychlorinated biphenyls (“PCBs”) or PCB-containing equipment used or stored on, and no
hazardous waste as defined by the Resource Conservation and Recovery Act, as amended, stored on, any site owned or operated by the Company, except for the storage of hazardous waste in compliance with Environmental Laws. The Company has made
available to the Purchasers true and complete copies of all material environmental records, reports, notifications, certificates of need, permits, pending permit applications, correspondence, engineering studies, and environmental studies or
assessments. 
 (b) For purposes of this Section 2.23, “Environmental Laws” means
any law, regulation, or other applicable requirement relating to (i) releases or threatened release of Hazardous Substance; (ii) pollution or protection of employee health or safety, public health or the environment; or (iii) the
manufacture, handling, transport, use, treatment, storage, or disposal of Hazardous Substances. 
 2.24
Disclosure. The Company has made available to the Purchasers all the information reasonably available to the Company that the Purchasers have requested for deciding whether to acquire the Shares, including certain of the Company’s
projections describing its proposed business plan (the “Business Plan”). To the Company’s knowledge, no representation or warranty of the Company contained in this Agreement, as qualified by the Disclosure Schedule, and no
certificate furnished or to be furnished to Purchasers at the Closing contains any untrue statement of a material fact or omits to state a material fact necessary in order to make the statements contained herein or therein not misleading in light of
the circumstances under which they were made. The Business Plan was prepared in good faith; however, the Company does not warrant that it will achieve any results projected in the Business Plan. It is understood that this representation is qualified
by the fact that the Company has not delivered to the Purchasers, and has not been requested to deliver, a private placement or similar memorandum or any written disclosure of the types of information customarily furnished to purchasers of
securities. 

  
 14 

 3. Representations and Warranties of the Purchasers. Each Purchaser hereby represents
and warrants to the Company, severally and not jointly, that: 
 3.1 Authorization. The Purchaser has full
power and authority to enter into the Transaction Agreements. The Transaction Agreements to which such Purchaser is a party, when executed and delivered by the Purchaser, will constitute valid and legally binding obligations of the Purchaser,
enforceable in accordance with their terms, except (a) as limited by applicable bankruptcy, insolvency, reorganization, moratorium, fraudulent conveyance, and any other laws of general application affecting enforcement of creditor’s rights
generally, and as limited by laws relating to the availability of specific performance, injunctive relief, or other equitable remedies, or (b) to the extent the indemnification provisions contained in the Investor Rights Agreement may be
limited by applicable federal or state securities laws. 
 3.2 Purchase Entirely for Own Account. This
Agreement is made with the Purchaser in reliance upon the Purchaser’s representation to the Company, which by the Purchaser’s execution of this Agreement, the Purchaser hereby confirms, that the Shares to be acquired by the Purchaser will
be acquired for investment for the Purchaser’s own account, not as a nominee or agent, and not with a view to the resale or distribution of any pan thereof, and that the Purchaser has no present intention of selling, granting any participation
in, or otherwise distributing the same. By executing this Agreement, the Purchaser further represents that the Purchaser does not presently have any contract, undertaking, agreement or arrangement with any Person to sell, transfer or grant
participations to such Person or to any third Person, with respect to any of the Shares. The Purchaser has not been formed for the specific purpose of acquiring the Shares. 

3.3 Disclosure of Information. The Purchaser has had an opportunity to discuss the Company’s business,
management, financial affairs and the terms and conditions of the offering of the Shares with the Company’s management and has had an opportunity to review the Company’s facilities. The foregoing, however, does not limit or modify the
representations and warranties of the Company in Section 2 of this Agreement or the right of the Purchasers to rely thereon. 
 3.4 Restricted Securities. The Purchaser understands that the Shares have not been, and will not be, registered under the Securities Act, by reason of a specific exemption from the registration
provisions of the Securities Act which depends upon, among other things, the bona fide nature of the investment intent and the accuracy of the Purchaser’s representations as expressed herein. The Purchaser understands that the Shares are
“restricted securities” under applicable U.S. federal and state securities laws and that, pursuant to these laws, the Purchaser must hold the Shares indefinitely unless they are registered with the Securities and Exchange Commission and
qualified by state authorities, or an exemption from such registration and qualification requirements is available. The Purchaser acknowledges that the Company has no obligation to register or qualify the Shares, or the Common Stock into which it
may be converted, for resale except as set forth in the Investors’ Rights Agreement. The Purchaser 

  
 15 

 
further acknowledges that if an exemption from registration or qualification is available, it may be conditioned on various requirements including, but not limited to, the time and manner of
sale, the holding period for the Shares, and on requirements relating to the Company which are outside of the Purchaser’s control, and which the Company is under no obligation and may not be able to satisfy. 

3.5 No Public Market. The Purchaser understands that no public market now exists for the Shares, and that the
Company has made no assurances that a public market will ever exist for the Shares. 
 3.6 Legends. The
Purchaser understands that the Shares and any securities issued in respect of or exchange for the Shares, may bear one or all of the following legends: 
 (a) “THE SHARES REPRESENTED BY THIS CERTIFICATE HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AND HAVE BEEN ACQUIRED FOR INVESTMENT AND NOT WITH A VIEW TO, OR IN CONNECTION WITH, THE
SALE OR DISTRIBUTION THEREOF. NO SUCH TRANSFER MAY BE EFFECTED WITHOUT AN EFFECTIVE REGISTRATION STATEMENT RELATED THERETO OR AN OPINION OF COUNSEL IN A FORM SATISFACTORY TO THE COMPANY THAT SUCH REGISTRATION IS NOT REQUIRED UNDER THE SECURITIES ACT
OF 1933.” 
 (b) Any legend set forth in, or required by, the other Transaction Agreements. 

(c) Any legend required by the securities laws of any state to the extent such laws are applicable to the Shares
represented by the certificate so legended. 
 3.7 Accredited Investor. The Purchaser is an accredited
investor as defined in Rule 501(a) of Regulation D promulgated under the Securities Act. 
 3.8 No General
Solicitation. Neither the Purchaser, nor any of its officers, directors, employees, agents, stockholders or partners has either directly or indirectly, including through a broker or finder (a) engaged in any general solicitation, or
(b) published any advertisement in connection with the offer and sale of the Shares. 
 3.9 Exculpation
Among Purchasers. Each Purchaser acknowledges that it is not relying upon any Person, other than the Company and its officers and directors, in making its investment or decision to invest in the Company. Each Purchaser agrees that no Purchaser
nor the respective controlling Persons, officers, directors, partners, agents, or employees of any Purchaser shall be liable to any other Purchaser for any action heretofore or hereafter taken or omitted to be taken by any of them in connection with
the purchase of the Shares. 
 3.10 Residence. If the Purchaser is an individual, then the Purchaser
resides in the state or province identified in the address of the Purchaser set forth on Exhibit A; if the Purchaser is a partnership, corporation, limited liability company or other entity, then the office or offices of the Purchaser in
which its principal place of business is identified in the address or addresses of the Purchaser set forth on Exhibit A. 

  
 16 

 4. Conditions to the Purchasers’ Obligations at Closing. 

(a) First Closing. The obligations of each Purchaser to purchase Shares at the First Closing are subject to the
fulfillment, on or before the First Closing, of each of the following conditions, unless otherwise waived. 

(i) Representations and Warranties. The representations and warranties of the Company contained in
Section 2 shall be true and correct in all material respects as of the First Closing, except that any such representations and warranties shall be true and correct in all respects where such representation and warranty is qualified with
respect to materiality. 
 (ii) Performance. The Company shall have performed and complied with all
covenants, agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by the Company on or before the First Closing. 

(iii) Compliance Certificate. The President of the Company shall deliver to the Purchasers at the First Closing a
certificate certifying that the conditions specified in Sections 4(a)(i) and 4(a)(ii) have been fulfilled. 
 (iv) Qualifications. All authorizations, approvals or permits, if any, of any governmental authority or regulatory body of the United States or of any state that are required in connection with the
lawful issuance and sale of the Shares pursuant to this Agreement shall be obtained and effective as of the First Closing. 
 (v) Opinion of Company Counsel. The Purchasers shall have received from Goodwin Procter LLP, counsel for the Company, an opinion, dated as of the First Closing, in substantially the form of
Exhibit H attached to this Agreement. 
 (vi) Board. The authorized size of the Board shall be six
(6) members, and the Board shall be comprised of Michael Steinmetz, Steve Gillis, Carl Weissman, Jay Hagan, Meenu Chhabra, and David Tirrell, as specified in the Stockholders Agreement. 

(vii) Board Leadership. Michael Steinmetz shall be appointed as Executive Chairman of the Board, as specified in
the Stockholders Agreement. 
 (viii) Investor Rights Agreement. The Company and each Purchaser (other
than the Purchaser relying upon this condition to excuse such Purchaser’s performance hereunder) and the other stockholders of the Company named as parties thereto shall have executed and delivered the Investor Rights Agreement. 

(ix) Stockholders Agreement. The Company, each Purchaser (other than the Purchaser relying upon this condition to
excuse such Purchaser’s performance hereunder), and the other stockholders of the Company named as parties thereto shall have executed and delivered the Stockholders Agreement. 

  
 17 

 (x) Restated Certificate. The Company shall have filed the Restated
Certificate with the Secretary of State of Delaware on or prior to the First Closing, which shall continue to be in full force and effect as of the First Closing. 

(xi) Secretary’s Certificate. The Secretary of the Company shall have delivered to the Purchasers at the
First Closing a certificate certifying (i) the Bylaws of the Company, (ii) resolutions of the Board approving the Transaction Agreements and the transactions contemplated under the Transaction Agreements, and (iii) resolutions of the
stockholders of the Company approving the Restated Certificate. 
 (xii) Proceedings and Documents. All
corporate and other proceedings in connection with the transactions contemplated at the First Closing and all documents incident thereto shall be reasonably satisfactory in form and substance to each Purchaser, and each Purchaser (or its counsel)
shall have received all such counterpart original and certified or other copies of such documents as reasonably requested. Such documents may include good standing certificates. 

(xiii) Management Rights. A Management Rights Letter shall have been executed by the Company and delivered to each
Purchaser who requested that one be delivered in connection with the First Closing. 
 (xiv) Conversion of
2007 Notes. The Company shall have converted the outstanding principal and interest on the Convertible Promissory Notes issued in the Company’s April 19, 2007 bridge financing into shares of Series A Preferred Stock. 

(b) Second Closing. The obligations of each Purchaser to purchase shares of Series B-2 Preferred Stock at the
Second Closing are subject to the fulfillment, on or before the Second Closing of each of the following conditions, unless otherwise waived: 
 (i) Representations and Warranties. The representations and warranties of each Purchaser contained in Section 3 shall have been true and correct in all material respects as of the First
Closing. 
 (ii) Performance. The Purchasers shall have performed and complied with all covenants,
agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by them on or before such Second Closing. 
 (iii) Milestones. Either (1) a majority of the Board has determined in good faith that the Company has achieved the Milestone Events outlined in Section 1.3 above, or (2) a
Majority Interest has waived in writing the failure of the Company to achieve the Milestone Events (as provided in Section 1.3(a) above). 
 5. Conditions of the Company’s Obligations at Closing. 

(a) First Closing. The obligations of the Company to sell Shares to the Purchasers at the First Closing are subject
to the fulfillment, on or before the First Closing of each of the following conditions, unless otherwise waived: 
 (i) Representations and Warranties. The representations and warranties of each Purchaser contained in Section 3 shall be true and correct in all material respects as of the First
Closing. 

  
 18 

 (ii) Performance. The Purchasers shall have performed and complied
with all covenants, agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by them on or before such First Closing. 

(iii) Qualifications. All authorizations, approvals or permits, if any, of any governmental authority or
regulatory body of the United States or of any state that are required in connection with the lawful issuance and sale of the Share pursuant to this Agreement shall be obtained and effective as of the Past Closing. 

(iv) Investor Rights Agreement. Each Purchaser shall have executed and delivered the Investor Rights Agreement.

 (v) Stockholders Agreement. Each Purchaser and the other stockholders of the Company named as parties
thereto shall have executed and delivered the Stockholders Agreement. 
 (b) Second Closing. The
obligations of the Company to sell Shares to the Purchasers at the Second Closing are subject to the fulfillment, on or before the Second Closing of each of the following conditions, unless otherwise waived: 

(i) Representations and Warranties. The representations and warranties of each Purchaser contained in
Section 3 shall be true and correct in all material respects as of the First Closing. 
 (ii)
Performance. The Purchasers shall have performed and complied with all covenants, agreements, obligations and conditions contained in this Agreement that are required to be performed or complied with by them on or before such Second Closing.

 (iii) Milestones. Either (1) a majority of the Board has determined in good faith that the
Company has achieved the Milestone Events in accordance with Section 1.3, or (2) a Majority Interest has waived in writing the failure of the Company to achieve the Milestone Events, as provided in Section 1.3(a) above.

 6. Miscellaneous. 
 6.1 Survival of Warranties. Unless otherwise set forth in this Agreement, the representations and warranties of the Company and the Purchasers contained in or made pursuant to this Agreement shall
survive the execution and delivery of this Agreement and the Closing and shall in no way be affected by any investigation or knowledge of the subject matter thereof made by or on behalf of the Purchasers or the Company. 

6.2 Successors and Assigns. The terms and conditions of this Agreement shall inure to the benefit of and be binding
upon the respective successors and assigns of the parties. Nothing in this Agreement, express or implied, is intended to confer upon any party other than the parties hereto or their respective successors and assigns any rights, remedies,
obligations, or liabilities under or by reason of this Agreement, except as expressly provided in this Agreement. 

  
 19 

 6.3 Governing Law. This Agreement and any controversy arising out of
or relating to this Agreement shall be governed by and construed in accordance with the General Corporation Law of the State of Delaware as to matters within the scope thereof, and as to all other matters shall be governed by and construed in
accordance with the internal laws of the State of New York, without regard to conflict of law principles that would result in the application of any law other than the law of the State of New York. 

6.4 Counterparts; Facsimile. This Agreement may be executed and delivered by facsimile signature and in two or more
counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. 
 6.5 Titles and Subtitles. The titles and subtitles used in this Agreement are used for convenience only and are not to be considered in construing or interpreting this Agreement. 

6.6 Notices. All notices and other communications given or made pursuant to this Agreement shall be in writing and
shall be deemed effectively given: (a) upon personal delivery to the party to be notified, (b) when sent by confirmed electronic mail or facsimile if sent during normal business hours of the recipient, and if not so confirmed, then on the
next business day, (c) five (5) days after having been sent by registered or certified mail, return receipt requested, postage prepaid, or (d) one (1) day after deposit with a nationally recognized overnight courier, specifying
next day delivery, with written verification of receipt. All communications shall be sent to the respective parties at their address as set forth on the signature page or Exhibit A, or to such e-mail address, facsimile number or address as
subsequently modified by written notice given in accordance with this Section 7.6. If notice is given to the Company, a copy shall also be sent to Goodwin Procter LLP, Exchange Place, 53 State Street Boston, MA 02109, Attn: James R.
Kasinger, Esq., (fax) 617-523-1231; (email)jkasinger@goodwinprocter.com and if notice is given to the Purchasers, a copy shall also be given to Orrick, Herrington & Sutcliffe LLP, 719 Second Avenue, Suite 900, Seattle, WA 98104, Attn:
Vincent A. Ricci, Esq., (fax) 206-839-4301; (email) vricci@orrick.com. 
 6.7 No Finder’s Fees. Each
party represents that it neither is nor will be obligated for any finder’s fee or commission in connection with this transaction. Each Purchaser agrees to indemnify and to hold harmless the Company from any liability for any commission or
compensation in the nature of a finder’s or broker’s fee arising out of this transaction (and the costs and expenses of defending against such liability or asserted liability) for which each Purchaser or any of its officers, employees, a
representatives is responsible. The Company agrees to indemnify and hold harmless each Purchaser from any liability for any commission or compensation in the nature of a finder’s or broker’s fee arising out of this transaction (and the
costs and expenses of defending against such liability or asserted liability) for which the Company or any of its officers, employees or representatives is responsible. 

  
 20 

 6.8 Fees and Expenses. At the First Closing, the Company shall pay
the reasonable fees and expenses of the counsel for the Purchasers, in an amount not to exceed, in the aggregate, $25,000. 
 6.9 Attorney’s Fees. finny action at law or in equity (including arbitration) is necessary to enforce or interpret the terms of any of the Transaction Agreements, the prevailing party shall be
entitled to reasonable attorney’s fees, costs and necessary disbursements in addition to any other relief to which such party may be entitled. 
 6.10 Amendments and Waivers. Any term of this Agreement may be amended, terminated or waived only with the written consent of the Company and the holders of a majority of the then-outstanding
Shares. Any amendment or waiver effected in accordance with this Section 6.10 shall be binding upon the Purchasers and each transferee of the Shares (or the Common Stock issuable upon conversion thereof), each future holder of all such
securities, and the Company. 
 6.11 Severability. The invalidity or unenforceability of any provision
hereof shall in no way affect the validity or enforceability of any other provision. 
 6.12 Delays or
Omissions. No delay or omission to exercise any right, power or remedy accruing to any party under this Agreement, upon any breach or default of any other party under this Agreement, shall impair any such right, power or remedy of such
non-breaching or non-defaulting party nor shall it be construed to be a waiver of any such breach or default, or an acquiescence therein, or of or in any similar breach or default thereafter occurring; nor shall any waiver of any single breach or
default be deemed a waiver of any other breach or default theretofore or thereafter occurring. Any waiver, permit, consent or approval of any kind or character on the part of any party of any breach or default under this Agreement, or any waiver on
the part of any party of any provisions or conditions of this Agreement, must be in writing and shall be effective only to the extent specifically set forth in such writing. All remedies, either under this Agreement or by law or otherwise afforded
to any party, shall be cumulative and not alternative. 
 6.13 Entire Agreement. This Agreement (including
the Exhibits and schedules hereto), the Restated Certificate and the other Transaction Agreements constitute the full and entire understanding and agreement between the parties with respect to the subject matter hereof, and any other written or oral
agreement relating to the subject matter hereof existing between the parties are expressly canceled. 
 6.14
Dispute Resolution. The parties (a) hereby irrevocably and unconditionally submit to the jurisdiction of the state courts of Washington and to the jurisdiction of the United States District Court for the Western District of Washington
for the purpose of any suit, action or other proceeding arising out of or based upon this Agreement, (b) agree not to commence any suit, action or other proceeding arising out of or based upon this Agreement except in the state courts of
Washington or the United States District Court for the Western District of Washington, and (c) hereby waive, and agree not to assert, by way of motion, as a defense, or otherwise, in any such suit, action or proceeding, any claim that it is not
subject personally to the jurisdiction of the above-named courts, that its property is exempt or immune 

  
 21 

 
from attachment or execution, that the suit, action or proceeding is brought in an inconvenient forum, that the venue of the suit, action or proceeding is improper or that this Agreement or the
subject matter hereof may not be enforced in or by such court. Each of the parties to this Agreement consents to personal jurisdiction for any equitable action sought in the U.S. District Court for the Western District of Washington or any court of
the State of Washington having subject matter jurisdiction. 
 6.15 Waiver of Existing Right of First
Refusal. In connection with the issuance of the Shares (and any shares of Common Stock or other capital stock issuable upon the conversion of any Shares), the undersigned, representing a majority-in-interest of the holders of Series A Preferred
Stock, hereby (i) waive the right of first refusal to future issuances of securities of the Company set forth in Section 3 of that certain Investor Rights Agreement dated as of October 19, 2005 among the Company and the other parties
thereto and any related notice rights pertaining thereto; and (ii) acknowledge and agree that such waiver shall be binding on the undersigned and each other party to such Investor Rights Agreement that is entitled to such right of first refusal
set forth in such Section 3. 
 6.16 Waiver of Conflicts. Each party to this Agreement acknowledges
that each of Goodwin Procter LLP, counsel for the Company, and Orrick, Herrington & Sutcliffe, LLP, counsel for the Purchasers, has in the past (i) performed and may continue to perform legal services for certain of the Purchasers, in
matters unrelated to the transactions described in this Agreement, including the representation of such Purchasers in venture capital financings and other matters and (ii) performed and may continue to perform legal services for other persons
or entities in whom the Purchasers have invested or may invest, including the representation of such other persons in venture capital financings in which the Purchasers have invested and other matters. Accordingly, each party to this Agreement
hereby (a) acknowledges that they have had an opportunity to ask for information relevant to this disclosure; and (b) gives its informed consent to each of Goodwin Procter LLP’s and Orrick, Herrington & Sutcliffe, LLP’s
representation of such other persons in such unrelated matters and to their representation of the Company and the Purchasers, respectively, in connection with this Agreement and the transactions contemplated hereby. Notwithstanding the foregoing,
this Section 6.16 does not apply to Amgen Ventures LLC. 
 [Remainder of Page Intentionally Left Blank] 

  
 22 

 EXHIBIT A 
 SCHEDULE OF PURCHASERS 
  

															
	 	  	First Closing	 	  	Second Closing	 
	 Name and Contact Information of

Purchaser
	  	Number of
Shares of
Series
B-1
Preferred
Stock	 	  	Aggregate
Purchase
Price	 	  	Number of
Shares of
Series B-2
Preferred
Stock (1)	  	Aggregate
Purchase
Price	 
	 ARCH Venture Fund V, L.P.
 8725
W. Higgins Road
 Suite 290
 Chicago, IL
60631
 Fax:      (773)380-4606

Attn:    Steve Gillis

Email:  sgillis@archventure.com
	  	 	1,504,484	  	  	$	1,504,484	  	  		  	$	1,221,517	  
					
	 ARCH V Entrepreneurs Fund, L.P.

8725 W. Higgins Road
 Suite 290

Chicago, IL 60631
 Fax:      (773) 380-6606

Attn:    Steve Gillis

Email:  sgillis@archventure.com
	  	 	10,137	  	  	$	10,137	  	  		  	$	8,230	  
					
	 ARCH Venture Fund VI, L.P.

8725 W. Higgins Road
 Suite 290

Chicago, IL 60631
 Fax:      (773) 380-6606

Attn:    Steve Gillis

Email:  sgillis@archventure.com
	  	 	2,475,000	  	  	$	2,475,000	  	  		  	$	1,430,000	  
					
	 Alexandria Equities, LLC
 385
East Colorado Boulevard
 Suite 299

Pasadena, CA 91101
 Fax:      (626) 578-0770

Ann:     Joel Marcus

Email:  jrnarcus@labspace.com
	  	 	910,260	  	  	$	910,260	  	  		  	$	606,840	  
					
	 Amgen Ventures LLC
 4445
Eastgate Mall
 Suite 230
 San Diego,
California 92121
 Attention: Joseph “Jay” Hagan
         Managing Director
 Email:  jhagan@amgen.com
 Facsimile: (858) 626-2709
	  	 	3,042,090	  	  	$	3,042,090	  	  		  	$	2,028,060	  

															
	 	  	First Closing	 	  	Second Closing	 
	 Name and Contact Information of

Purchaser
	  	Number of
Shares of
Series
B-1
Preferred
Stock	 	  	Aggregate
Purchase
Price	 	  	Number of
Shares of
Series B-2
Preferred
Stock (1)	  	Aggregate
Purchase
Price	 
	 MPM BioVentures III, L.P.
 The
John Hancock Tower
 200 Clarendon Street, 54th Floor
 Boston, MA 02116

Fax:      (617) 425-9201

Attn:    Lauren Fiore

  Michael Steinmetz
 Email:  lfiore@mpmcapital.com

  msteinmetz@clarusventures.com
	  	 	339,649	  	  	$	339,649	  	  		  	$	226,433	  
					
	 MPM BioVentures III-QP, L.P.

The John Hancock Tower
 200 Clarendon Street,
54th Floor
 Boston, MA 02116
 Fax:      (617) 425-9201

Attn:    Lauren Fiore

  Michael Steinmetz
 Email:  lfiore@mpmcapital.com

  msteinmetz@clarusventures.com
	  	 	5,051,481	  	  	$	5,051,481	  	  		  	$	3,367,655	  
					
	 MPM BioVentures III GmbH & Co.
 Beteiligungs KG
 The John Hancock Tower
 200 Clarendon Street, 54th Floor
 Boston, MA 02116

Fax:      (617) 425-9201

Attn:    Lauren Fiore

  Michael Steinmetz
 Email:  lfiore@mpmcapital.com

  msteinmetz@clarusventures.com
	  	 	426,913	  	  	$	426,913	  	  		  	$	284,608	  
					
	 MPM BioVentures III Parallel Fund, L.P.
 The John Hancock Tower
 200 Clarendon Street, 54th Floor

Boston, MA 02116
 Fax:      (617) 425-9201

Attn:    Lauren Fiore

  Michael Steinmetz
 Email:  lfiore@mpmcapital.com

  msteinmetz@clarusventures.com
	  	 	152,560	  	  	$	152,560	  	  		  	$	101,707	  
					
	 MPM Asset Management Investors 2003
 BVIII LLC
 The John Hancock Tower
 200 Clarendon Street, 54th Floor
 Boston, MA 02116

Fax:      (617) 425-9201

Attn:    Lauren Fiore

  Michael Steinmetz
 Email:  lfiore@mpmcapital.com

  msteinmetz@clarusventures.com
	  	 	97,805	  	  	$	97,805	  	  		  	$	65,203	  

															
	 	  	First Closing	 	  	Second Closing	 
	 Name and Contact Information of

Purchaser
	  	Number of
Shares of
Series
B-1
Preferred
Stock	 	  	Aggregate
Purchase
Price	 	  	Number of
Shares of
Series B-2
Preferred
Stock (1)	  	Aggregate
Purchase
Price	 
	 OVP Venture Partners VI, L.P.

c/o OVP Venture Partners
 1010 Market
Street
 Kirkland, WA 98033
 Attn:    Bill Funcannon

Fax:      (425) 889-0152

Email:  funcannon@ovp.com
   waite@ovp.com
	  	 	3,909,829	  	  	$	3,909,829	  	  		  	$	2,606,552	  
					
	 OVP VI Entrepreneurs Fund, L.P.

c/o OVP Venture Partners
 1010 Market
Street
 Kirkland, WA 98033
 Attn:    Bill Funcannon

Fax:      (425) 889-0152

Email:  funcannon@ovp.com
   waite@ovp.com
	  	 	79,792	  	  	$	79,792	  	  		  	$	53,195	  

  

	(1)	The number of Shares of Series B-2 Preferred Stock to be purchased shall be calculated by dividing the aggregate purchase price by the applicable Second Closing
Purchase Price.

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00194-of-00352.parquet"}]]